Emerging and Non-Traditional Risk Factors for Heart Disease

Introduction

Cardiovascular disease (CVD) risk has traditionally been assessed using factors such as dyslipidemia, hypertension, diabetes, smoking, and family history. However, emerging research highlights **non-traditional risk factors** that also contribute to atherosclerosis and heart disease. These include chronic oral infections (periodontal disease), systemic immune activation (inflammation and autoimmunity), clonal mutations in blood stem cells, gut microbiome-derived metabolites, and environmental pollutants. This report examines each of these categories in detail, discussing their mechanisms of action, supporting studies, comparisons to traditional risk factors, and potential clinical implications.

Dental Health – Periodontitis and Cardiovascular Risk

Epidemiological studies have established a significant association between chronic periodontal disease (gum disease) and CVD. Meta-analyses encompassing tens of thousands of patients show that **periodontitis confers about a 1.1- to 2.2-fold increased risk for coronary heart disease**, even after adjusting for traditional risk factorsmdpi.com. Longitudinal data further validate this link, and importantly, intervention trials indicate it may be causal: treatment of periodontitis in affected patients significantly **improves endothelial function** (flow-mediated dilation) within monthsmdpi.com. For example, a systematic review of 14 randomized trials found that periodontal therapy led to marked improvement in vascular endothelial performance, highlighting a potential reversibility of risk with oral caremdpi.com. These findings underscore that poor dental health is not merely a bystander but can actively contribute to heart disease risk.

Mechanistically, periodontitis produces a state of chronic, low-grade systemic inflammation that can **accelerate atherosclerosis**. In advanced gum disease, the inflamed periodontal tissues release pro-inflammatory cytokines like interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and IL-6 into circulationmdpi.com. These cytokines injure vascular endothelium, promote leukocyte recruitment to vessel walls, and exacerbate the formation of atherosclerotic plaquesmdpi.com. Elevated C-reactive protein (CRP) and IL-6 levels are frequently observed in individuals with severe periodontitis, reflecting this systemic inflammatory burdenmdpi.com. Furthermore, **periodontal pathogens and their virulence factors can directly infiltrate the bloodstream** during chewing or tooth brushing, seeding distant sites. DNA from oral bacteria (e.g. *Porphyromonas gingivalis* and *Aggregatibacter actinomycetemcomitans*) has been

detected within atheromatous plaques, supporting a direct microbial contribution to plaque developmentmdpi.com. These bacteria and their antigens may incite local inflammation in arteries and even trigger autoimmune reactions through molecular mimicry (e.g. cross-reactivity between bacterial heat-shock proteins and host proteins in the arterial wall)mdpi.com. Oxidative stress is another bridge: neutrophils activated by oral infection release reactive oxygen species that damage the endothelium and oxidize LDL, fostering foam cell formationmdpi.com. In essence, **periodontal disease propagates many of the same pathways as traditional risk factors** (inflammation, oxidative stress, endothelial dysfunction) and thereby contributes to CVD pathogenesis.

Compared to established risk factors, the magnitude of risk imposed by severe periodontitis (up to ~2-fold increase in heart disease risk) is in the same ballpark as a moderate elevation in cholesterol or blood pressure. Unlike hypertension or hyperlipidemia, which directly affect hemodynamics and plaque composition, periodontitis influences cardiovascular risk indirectly via immune-mediated mechanisms. Nonetheless, the clinical relevance is considerable: periodontitis is common and often under-recognized in cardiovascular prevention. These insights have practical implications – **maintaining good oral hygiene and treating gum disease** may be an important adjunct strategy to reduce cardiovascular risk. Some healthcare guidelines now emphasize periodontal evaluation in patients with high CVD risk. Ongoing trials are exploring whether aggressive periodontal therapy can translate into fewer cardiac events. While more evidence is needed, the oral-systemic health connection exemplifies how a localized chronic infection can have systemic consequences for the heartmdpi.com. At a minimum, physicians and dentists should collaborate in managing patients' oral health as part of comprehensive cardiovascular prevention.

Chronic Inflammation and Immune Activation in Atherosclerosis

Atherosclerosis is now understood as not just a lipid-storage disease, but also a chronic **inflammatory** condition of the arterial wall. Immune activation plays a central role in every stage of atherosclerosis – from plaque initiation to rupturefrontiersin.orgfrontiersin.org. In the early steps, elevated circulating cytokines and adhesion molecules drive recruitment of leukocytes (monocytes and T-lymphocytes) to the endothelium, where they transmigrate and contribute to fatty streak formationfrontiersin.org. As lesions progress, **activated macrophages and T-cells within plaques sustain local inflammation**, secreting interleukins, interferon-γ, and other mediators that perpetuate foam cell formation and smooth muscle proliferationfrontiersin.org. Inflammatory enzymes (like matrix metalloproteinases from macrophages) degrade the fibrous cap, making plaques fragile and prone to rupturefrontiersin.org. Thus, inflammation both promotes plaque growth and increases the likelihood of thrombosis – the trigger for heart attacks and strokes.

Systemic inflammatory markers strongly correlate with cardiovascular risk. For instance,

high-sensitivity C-reactive protein (hs-CRP) – an acute phase reactant and proxy for IL-6 activity – is a robust independent predictor of myocardial infarction. Healthy individuals with hs-CRP in the top quartile have about a **2–3 fold higher risk of future heart attack** compared to those in the lowest quartile, even after controlling for cholesterol, blood pressure, and other factorsfrontiersin.org. This was first shown in the landmark Physician's Health Study and confirmed in multiple cohorts: inflammation confers risk beyond what traditional factors explainfrontiersin.org. Likewise, chronic inflammatory diseases offer a human "model" of amplified immune activation: patients with rheumatoid arthritis or lupus develop premature and accelerated atherosclerosis. Epidemiologic data indicate that rheumatoid arthritis (an autoimmune disorder with chronic cytokine elevation) is associated with roughly **50%–70% higher risk of cardiovascular events** compared to the general populationecrjournal.com. Notably, this excess risk is not fully accounted for by traditional factors, implicating persistent inflammation as the driver. These observations align with the concept of an "inflamed phenotype" conferring cardiovascular hazard analogous to, for example, having diabetes or smoking.

The key mediators have been identified: **the IL-1→IL-6 signaling axis** is paramount in atherogenesisfrontiersin.org. Cholesterol crystals and other danger signals in plaques activate the NLRP3 inflammasome in macrophages, leading to release of IL-1β. IL-1 in turn triggers endothelial cells to express adhesion molecules and recruits more leukocytesfrontiersin.org. IL-1β also stimulates production of IL-6, which acts on the liver to raise CRP and serum amyloid Afrontiersin.org. IL-6 has direct effects on plaque as well, promoting endothelial dysfunction and leukocyte recruitment. This IL-1/IL-6 pathway links innate immunity to liver acute-phase responses and vascular injuryfrontiersin.org. The pathogenic role of these cytokines is strongly supported by clinical trials. The **CANTOS trial** (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) provided a breakthrough in 2017: in patients with prior myocardial infarction and residual inflammation (CRP ≥2 mg/L), targeting IL-1β with canakinumab led to a **15% reduction in major cardiovascular events** compared to placebofrontiersin.org. Importantly, canakinumab had no effect on LDL cholesterol – it improved outcomes purely by dampening inflammation. This was the first hard evidence that immune modulation alone can lower cardiovascular event rates, thus validating inflammation as a true causal risk factor in coronary diseasefrontiersin.org. Similarly, low-dose colchicine (an inexpensive anti-inflammatory) has demonstrated reductions in recurrent heart attack and stroke in trials (COLCOT, LoDoCo2), presumably by suppressing neutrophil and inflammasome activity in plaques.

In comparison to traditional factors, chronic inflammation's impact on risk is substantial and potentially synergistic with other factors. For example, an individual with high LDL but also high CRP is at especially high risk – and achieving both LDL-lowering *and* CRP-lowering yields the best outcomesfrontiersin.orgfrontiersin.org. We now recognize that about one-third of treated patients have "residual inflammatory risk" (elevated CRP despite controlled LDL), which can be targeted with specific therapies. From a clinical standpoint, these discoveries are shifting paradigms. There is growing interest in measuring inflammatory markers (like CRP or IL-6) as part of risk stratification, and in using immunomodulatory treatments in select patients. The

concept of the “inflamed plaque” has also spurred development of novel drugs (e.g. NLRP3 inhibitors, IL-6 inhibitors) for atherosclerosisfrontiersin.org. In summary, immune activation is a critical, non-traditional risk factor for heart disease – one that **intersects with classical risk factors** (many of which, like obesity or infection, cause inflammation) yet provides an independent avenue for intervention. Controlling inflammation, much like controlling blood pressure or cholesterol, has emerged as a viable strategy to prevent cardiovascular events.

Clonal Hematopoiesis and Blood Stem Cell Mutations (CHIP and MPNs)

In recent years, researchers uncovered a surprising risk factor arising from our own blood stem cells. **Clonal hematopoiesis of indeterminate potential (CHIP)** refers to age-related DNA mutations in hematopoietic stem cells that give rise to a dominant mutant blood cell clone, in the absence of leukemia or other blood cancer. CHIP is common – detectable in ~10–20% of people over 70 – and was initially linked to higher leukemia risk. However, it has now emerged as a **potent and independent risk factor for atherosclerotic cardiovascular disease**pubmed.ncbi.nlm.nih.govacc.org. A landmark 2017 study showed that individuals with CHIP had nearly *double* the risk of coronary artery disease compared to those without CHIP, despite similar profiles in traditional risk factorsacc.org. Particularly, mutations in certain genes (like *TET2* or *JAK2*) conferred the greatest risk. Carriers of a *JAK2* V617F mutation (a common CHIP mutation) were found to have a **4-fold higher incidence of early myocardial infarction** in one analysisacc.org. To put this in perspective, the presence of a high-risk CHIP clone can elevate heart attack risk on the order of a major cholesterol abnormality. This connection helps explain some “residual risk” in the population – people who suffer heart disease events despite optimal control of traditional risk factors might have an occult driver in their bone marrow.

The mechanism linking **mutant blood clones to cardiovascular damage** is chronic inflammation. The mutant hematopoietic stem cell gives rise to a disproportionate number of circulating leukocytes (monocytes, macrophages) that are functionally altered to be more pro-inflammatory. Elegant experiments have demonstrated causality: when a hyperactive *TET2*-mutant clone was introduced into atherosclerosis-prone mice, the animals developed larger, more inflamed plaques than control miceacc.org. *TET2* normally helps repress inflammatory gene expression in macrophages; its loss of function lifts this brake, resulting in macrophages that secrete excess IL-1β and IL-6acc.org. The *TET2*-deficient macrophages exhibit heightened NLRP3 inflammasome activity, pumping out IL-1β that accelerates plaque growthacc.org. Similarly, the *JAK2 V617F* mutation (which constitutively activates JAK-STAT signaling) skews marrow output toward pro-inflammatory myeloid cells. *JAK2*-mutant monocytes produce more IL-1β and also IL-6; they tend to accumulate in lesions and form a large necrotic core within plaquesacc.org. Notably, in a mouse model, *JAK2* mutation led to aggressive atherogenesis which **could be mitigated by IL-1β blockade** – linking the mutation’s effect specifically to inflammasome/IL-1 activityacc.org. These findings align with human trial data: a secondary analysis of CANTOS found that patients with CHIP (especially *TET2* mutations)

derived particular benefit from canakinumab (IL-1β inhibitor), suggesting that the excess risk from CHIP is indeed driven by IL-1-mediated inflammationacc.org. In essence, **CHIP creates an overactive immune system** that contributes to arterial disease, echoing the inflammation theme seen with other risk factors.

Clonal hematopoiesis exists on a continuum with hematologic neoplasms. If additional mutations accumulate, CHIP can progress to a **myeloproliferative neoplasm (MPN)** such as polycythemia vera or essential thrombocythemia – overt cancers that dramatically increase blood counts. Patients with MPNs have long been known to suffer high rates of cardiovascular complications, particularly **arterial thrombosis, heart failure, and accelerated atherosclerosis**pmc.ncbi.nlm.nih.gov. For example, essential thrombocythemia patients with a *JAK2* mutation have about a 2.5-fold higher risk of arterial blood clots (heart attack, stroke) than those with other driver mutationspmc.ncbi.nlm.nih.gov. In polycythemia vera, increased hematocrit leads to hyperviscosity and thrombosis, but even beyond that, these disorders cause chronic cytokine release (e.g. elevated IL-8, TNF-α) which likely damages vessels over time. Thus, the *JAK2 V617F* mutation – whether as CHIP or as an MPN – is particularly atherogenic, acting through both inflammation and hematologic stress. The convergence of evidence from human genomics, animal models, and clinical outcomes makes a compelling case that **somatic mutations in blood cells can drive CVD** on par with inherited risk factors.

From a clinical standpoint, this is a paradigm shift. Currently, there is no routine screening for CHIP in cardiology, but that may change as we learn more. It has been proposed that elderly patients or those with unexplained early heart disease could be tested for CHIP mutations (via blood DNA sequencing) to refine risk assessmentpubmed.ncbi.nlm.nih.gov. If a high-risk mutation like *JAK2* is found, more aggressive management of other factors or preventative anti-inflammatory therapy might be warranted (clinical trials are being designed to test this approach). Additionally, therapies targeting the clone itself are conceivable – for instance, *JAK2* inhibitors (used in MPN treatment) or future drugs that selectively suppress CHIP clones could lower cardiovascular risk in mutation carrierspubmed.ncbi.nlm.nih.gov. The field of "cardio-oncology" is now broadening to include these considerations of clonal hematopoiesis. In summary, **CHIP and MPNs represent a novel class of risk factors rooted in genomic instability and inflammation**. They highlight how the hematologic and cardiovascular systems are interconnected, and they open new avenues for personalized risk prediction and therapy in heart disease.

Gut Microbiome and Cardiovascular Disease Metabolites

Figure: The gut microbiome forms a dense microbial community (multicolored bacteria) along the intestinal lining. **Microbial metabolites** such as TMAO and imidazole propionate can enter the circulation and adversely affect blood vessels, linking gut ecology to atherosclerosis.

One of the most intriguing non-traditional risk factors for heart disease is the **gut microbiome**, the trillions of microbes residing in the gastrointestinal tract. Diet–microbe interactions can

produce metabolites that influence the host's cardiovascular system. The exemplar case is **trimethylamine-N-oxide (TMAO)**, a molecule generated when gut bacteria digest nutrients like choline, phosphatidylcholine, and L-carnitine (abundant in red meat, egg yolk, etc.). Dietary choline and carnitine are first converted by intestinal microbes to trimethylamine (TMA), which is then oxidized in the liver to TMAOfrontiersin.org. Research by Wang, Hazen and colleagues a decade ago revealed a striking connection: elevated blood TMAO levels are associated with **increased risks of major adverse cardiovascular events (MACE)**, including heart attack and strokefrontiersin.org. In multiple cohorts, individuals with high TMAO had significantly higher incidence of coronary events, even after adjusting for traditional factors like LDL cholesterolfrontiersin.org. One prospective study found that those in the top quartile of TMAO had around a **2.5-fold greater risk of a heart attack or stroke** compared to the bottom quartile, independent of classic risk markers. These findings have been reproduced, positioning TMAO as an **independent prognostic marker** for CVDfrontiersin.org. In fact, adding TMAO to risk models modestly improves prediction of events beyond traditional factors, suggesting it captures an aspect of risk not otherwise accounted for (likely related to diet and microbiome function).

Beyond being a marker, TMAO appears to be mechanistically involved in atherogenesis. It **promotes inflammation and endothelial dysfunction** through multiple pathways. Experiments in vitro and in animals indicate that TMAO can activate endothelial cells to secrete chemokines and express adhesion molecules that attract monocytesfrontiersin.org. TMAO has been shown to activate the NF-κB pathway in vascular cells, resulting in increased expression of TNF-α, IL-6, and other pro-inflammatory mediatorsfrontiersin.org. It also triggers **NLRP3 inflammasome activation** in macrophages, leading to the release of IL-1β and IL-18, which exacerbate vascular inflammationfrontiersin.org. This mirrors the same dangerous cytokine cascade implicated in other risk factors. Additionally, TMAO affects cholesterol metabolism in the arterial wall – studies suggest it *impairs reverse cholesterol transport* (the process by which cholesterol is effluxed from foam cells and returned to the liver) and enhances foam cell formation, thereby accelerating plaque buildup. Another documented effect is on platelets: TMAO **increases platelet reactivity**, making blood more prone to thrombosisfrontiersin.org. In mouse models, feeding a TMAO-rich diet or its precursors leads to faster plaque development and a pro-thrombotic tendency, whereas suppressing gut TMA production (using antibiotics or enzyme inhibitors) has been shown to reduce atherosclerosisfrontiersin.orgfrontiersin.org. In summary, TMAO is not just a passive marker but **actively contributes to atherothrombosis** via inflammatory and metabolic perturbations.

Another emerging microbiome-linked factor is **imidazole propionate (ImP)**, a metabolite derived from bacterial fermentation of the amino acid histidine. ImP was initially known for its role in metabolic disorders (it accumulates in some people with type 2 diabetes). New evidence now implicates ImP in cardiovascular disease. A 2025 study by Mastrangelo *et al.* (published in *Nature*) identified ImP as a **key microbial metabolite elevated in early atherosclerosis**genengnews.com. In atherosclerosis-prone mice, blood ImP levels rose concomitantly with plaque development, and importantly, ImP levels were higher in humans with

subclinical arterial plaques compared to those withoutgenengnews.comgenengnews.com. This suggests ImP might serve as a marker of “active” atherosclerosis. More strikingly, the researchers demonstrated causality: administering ImP to otherwise healthy mice *induced endothelial dysfunction and robust atherosclerotic plaque formation*genengnews.com. Mice given ImP developed significantly more aortic plaque despite having normal plasma cholesterol, indicating ImP can drive atherogenesis **independent of lipid levels**genengnews.com. ImP accomplished this by stimulating both innate and adaptive immune responses – treated mice showed heightened vascular inflammation with increased immune cell infiltration in their arteriesgenengnews.com. The mechanism was traced to ImP’s activation of the **imidazoline-1 receptor (I1R)** on myeloid cells, which triggers systemic inflammation and foam cell formationgenengnews.com. When the I1R receptor was pharmacologically blocked, ImP could no longer cause atherosclerosis in the micegenengnews.comgenengnews.com. Thus, ImP is a newly identified **causal agent of atherosclerosis**, linking certain gut bacterial activities to arterial disease. Notably, ImP has also been associated with cardiometabolic conditions in humans: beyond atherosclerosis, elevated ImP was previously found in patients with coronary artery disease, heart failure, and in HIV-positive people with heightened cardiovascular riskgenengnews.com. It appears to be a multifaceted disruptor of normal metabolic and vascular physiology.

The gut microbiome’s contribution to CVD adds a nuanced layer to our understanding of risk, often mediating the effects of diet. For instance, we have long known that a diet high in red meat is associated with heart disease; TMAO provides a **mechanistic link** – red meat contains carnitine which gut bacteria convert to TMAO, thus connecting diet to plaque via microbial metabolism. These risk factors are non-traditional in the sense that they are **extrinsic to the human genome** (residing in gut flora) yet are modifiable via diet, prebiotics/probiotics, or even antibiotics. In terms of effect size, microbiome factors like TMAO or ImP generally elevate risk to a lesser degree than, say, familial hypercholesterolemia or heavy smoking, but they may be on par with mild hypertension or overweight in their hazard ratio. Moreover, they likely interact with traditional factors: e.g. a person with high cholesterol and high TMAO might be at particularly high risk. Clinically, this area is in its infancy, but potential interventions are being explored. Dietary modification is the most immediate: reducing consumption of animal products that feed TMAO-producing bacteria (and instead favoring plant-based diets) can lower TMAO levels. In fact, studies show vegetarians have markedly lower TMAO levels for the same food intake than omnivores, due to different gut microbial populations. Probiotics or selective antibiotics might one day be used to *reshape the gut microbiota* toward a less pro-atherogenic composition. Another intriguing approach is developing **enzyme inhibitors** that prevent TMA formation – a compound called DMB (3,3-dimethyl-1-butanol) has been shown in animals to inhibit microbial TMA production and reduce atherosclerosis. Similarly, following the ImP discovery, researchers suggested that **blocking the ImP–I1R pathway** could become a therapeutic strategygenengnews.com. They demonstrated that combining an I1R blocker with a statin had additive benefits in mice, pointing to a future where microbiome-targeted drugs plus conventional therapies yield synergistic protectiongenengnews.com. In summary, the gut microbiome is a frontier of cardiovascular risk research – it underscores the role of the

“microbial organ” in human physiology and offers exciting prospects for novel diagnostics (e.g. TMAO or ImP blood tests as risk markers) and treatments to complement traditional risk factor management.

Environmental Pollutants and Cardiovascular Disease (Air Pollution, Metals, and Endocrine Disruptors)

Environmental factors, long overlooked in cardiovascular medicine, are now recognized as **direct causative agents for heart disease** on a global scale. Chief among these is **air pollution**, particularly fine particulate matter ($PM_{2.5}$, particles ≤2.5 microns in diameter) generated by vehicle emissions, industrial processes, wildfires, and other sources. Epidemiological studies and burden-of-disease analyses reveal that air pollution rivals traditional factors in its impact. In 2019, an estimated 9 million premature deaths worldwide were attributable to pollution, of which **nearly 62% were due to cardiovascular causes**nejm.org. Put differently, it’s been reported that *almost 20% of all CVD deaths globally are attributable to ambient air pollution*, making it the **4th leading cardiovascular risk factor** after hypertension, poor diet, and smokingahajournals.org. Breathing polluted air (such as smog in urban centers) thus confers a level of risk comparable to second-hand smoke or a chronic heavy smoking habit in some regionsahajournals.orgnejm.org. Both short-term spikes in pollution (over days) and long-term exposure (over years) are harmful. Acute exposure to high $PM_{2.5}$ can trigger myocardial infarctions, arrhythmias, and heart failure exacerbations – likely by causing surges in blood pressure, oxidative stress, and coagulability. Long-term exposure accelerates atherosclerosis development and increases hypertension incidence, as demonstrated by many cohort studies linking residential pollution levels to cardiovascular eventsjamanetwork.comworld-heart-federation.org. In fact, chronic $PM_{2.5}$ exposure is associated with coronary artery calcium progression (a measure of subclinical plaque) and higher carotid intima-media thickness, indicating that pollution literally **ages** the vasculature.

The mechanisms by which fine particulates and other pollutants damage the cardiovascular system are intensively studied. When inhaled, $PM_{2.5}$ can penetrate deep into the lungs, **inducing pulmonary inflammation and oxidative stress**. Inflammatory cytokines (IL-6, IL-1β, etc.) and pro-oxidant molecules then spill into the circulation, causing systemic endothelial dysfunction. $PM_{2.5}$ also **increases oxidative stress within blood vessels**, directly or via ultrafine particles that translocate into the bloodstream, leading to reduced nitric oxide availability and a propensity for vasoconstriction and thrombosisprofessional.heart.org. Additionally, particulate pollutants can trigger autonomic nervous system imbalances – for example, acute pollution exposure is known to increase sympathetic activity, which can raise blood pressure and precipitate arrhythmias (even sudden cardiac death in vulnerable individuals). Chronic exposure leads to sustained **arterial inflammation, accelerated atherosclerotic plaque formation, and instability** of plaques. Pathologically, animal models exposed to realistic air pollution develop larger atherosclerotic lesions with more macrophages and lipid content. There is also evidence that pollutant chemicals (like polycyclic aromatic

hydrocarbons adhering to particles) can directly **injure endothelial cells and mutate DNA**, compounding risk. In summary, air pollution acts similarly to smoking in that it introduces a mix of oxidants and toxins into the body, provoking inflammation, oxidative damage, dyslipidemia (pollution has been linked to lower HDL levels), and hypercoagulability. The scope of this risk factor is enormous – virtually entire populations have some degree of exposure. Accordingly, public health measures to improve air quality are viewed as crucial cardiovascular prevention strategies. Notably, countries that have implemented clean air laws have seen subsequent reductions in heart attack and stroke rates, reinforcing causality. Clinicians now consider high pollution days as a trigger for events, and sensitive patients (like those with known coronary disease) are advised to avoid heavy exertion or wear filtration masks during such times.

Beyond air pollution, **heavy metals** and industrial chemicals present in the environment can also promote cardiovascular disease. The American Heart Association in 2021 issued a scientific statement declaring that contaminants like **lead, cadmium, and arsenic** are **established cardiovascular risk factors**professional.heart.org. These toxic metals are pervasive: lead and cadmium are found in tobacco smoke, certain foods, and formerly in paints and gasoline; arsenic can contaminate groundwater in various regions. Chronic exposure to even low levels of these metals has been linked to **hypertension, coronary artery disease, peripheral artery disease, and cardiovascular mortality**professional.heart.org. For example, long-term lead exposure has a causal association with elevated blood pressure – lead interferes with nitric oxide signaling in vessels (via calmodulin-dependent processes), leading to vascular stiffness and hypertensionbmcpublichealth.biomedcentral.com. Lead and cadmium both induce **oxidative stress and endothelial dysfunction**, as they generate reactive oxygen species and deplete antioxidants in endothelial cellsprofessional.heart.org. They also cause **chronic inflammation**: studies show higher blood lead or cadmium correlates with increased CRP and inflammatory cytokines. Arsenic, often ingested through contaminated water, has been implicated in arteriosclerosis; it can cause endothelial cell injury and has pro-inflammatory, pro-thrombotic effects (historically, arsenic exposure in Taiwan was associated with “blackfoot disease” – severe peripheral atherosclerosis). The evidence for metals is now considerable – prospective studies find that individuals with higher baseline levels of lead or cadmium have significantly greater risk of heart attacks and stroke over timeprofessional.heart.org. One meta-analysis in *BMJ* 2018 showed that blood lead in the upper range (but below clinical poisoning levels) was associated with a marked increase in ischemic heart disease deathsprofessional.heart.org. Cadmium, often coming from cigarette smoke or certain rice grains, has been linked to peripheral artery disease and heart failure. The **mechanistic abnormalities** caused by these metals include genomic instability (they can impair DNA repair), adverse lipid changes, kidney damage (which secondarily raises blood pressure), and direct myocardial toxicity at higher dosesprofessional.heart.org. Indeed, autopsies of young accident victims have found that higher bone lead levels correlate with more atherosclerotic lesions, supporting a direct pathogenic role.

It is worth noting that the cardiovascular effects of toxic metals are **preventable and treatable** in principle. Public health actions like removal of lead from gasoline and paint have dramatically

lowered population blood lead levels, correlating with declines in average blood pressure over decades. Unfortunately, exposure disparities exist – communities of lower socioeconomic status or certain occupations (like battery recycling) have higher heavy metal burdens, contributing to health inequitiesprofessional.heart.org. Clinically, chelation therapy to remove metals has shown some promise: the Trial to Assess Chelation Therapy (TACT) found that EDTA chelation in post-MI patients (particularly those with diabetes) modestly reduced recurrent cardiovascular events, presumably by reducing body lead/cadmium storesprofessional.heart.org. While chelation isn't standard therapy, these results underscore that metals were likely contributing to risk in those patients, and removing them yielded benefit. Moving forward, better screening for chronic metal exposure (through blood or urine tests) in high-risk patients might be considered, and avoiding exposure (e.g. quitting smoking to reduce cadmium intake, ensuring safe water to avoid arsenic) should be part of lifestyle counseling when relevant.

Another category of non-traditional risk factors is **endocrine-disrupting chemicals** – man-made compounds that interfere with hormonal systems. Among these, **bisphenol A (BPA)** and phthalates (found in plastics, receipts, personal care products, etc.) have drawn attention for their cardiometabolic effects. BPA is ubiquitous and trace amounts are detectable in most people. Research suggests that higher circulating or urinary BPA levels correlate with **increased prevalence of heart disease, hypertension, and diabetes**mdpi.com. For instance, analyses of U.S. NHANES data have found that individuals in the top quartile of BPA exposure had higher odds of coronary artery disease compared to those in the lowest quartile, even after adjusting for traditional risks. Prospective data are more limited, but one study reported that BPA levels were significantly associated with **higher risk of all-cause and CVD mortality** over ~10 years of follow-upmdpi.commdpi.com. Mechanistically, BPA can bind to estrogen receptors and other nuclear receptors in the cardiovascular system, leading to aberrant signaling. In cardiac myocytes and arterial cells, BPA exposure has been shown to provoke **arrhythmogenic effects and hypertrophy** in experimental modelsjamanetwork.com. BPA can trigger calcium handling abnormalities in heart muscle, potentially explaining links to arrhythmias. It also appears to promote oxidative stress and inflammation in endothelial cells, and to disrupt adipocyte and pancreatic beta-cell function (contributing to insulin resistance). Animal studies confirm that chronic low-dose BPA exposure leads to elevated blood pressure and aggravated atherosclerosis – likely through a combination of sympathetic activation and endothelial dysfunction. **Phthalates**, similarly, have been associated epidemiologically with higher blood pressure and insulin resistance in children and adults. They may act via inducing oxidative stress and interfering with thyroid and sex hormone receptors that are important for cardiovascular homeostasis. While the effect sizes of any single endocrine disruptor on CVD risk are modest (and confounding factors are a challenge), the **chronic cumulative exposure** to these chemicals in modern life raises concern. Regulatory efforts to limit BPA in food containers and phthalates in cosmetics stem not only from cancer or reproductive toxicity fears, but also from these potential cardiometabolic harms.

In comparing environmental pollutants to traditional risk factors, there are both similarities and critical differences. Like smoking (which is essentially voluntary inhalation of toxic particles and

chemicals), **air pollution and toxic metals drive CVD via inflammation, oxidative injury, and endothelial damage** – fundamental processes also triggered by hypertension (via biomechanical stress) or diabetes (via hyperglycemic toxicity)professional.heart.org. What sets pollutants apart is that exposure is often beyond an individual's immediate control and can affect large populations indiscriminately. A key example is the widespread impact of air quality: whereas smoking primarily affects smokers (and second-hand those around them), *everyone* in a polluted city is at risk, including children and the elderly. Thus, at a population scale, pollution can cause more aggregate CVD burden than some traditional factors. The fact that 1 in 5 cardiovascular deaths globally is due to air pollution is a staggering statistic that reframes "environmental health" as "cardiovascular health"ahajournals.org. Another difference is in awareness – patients and clinicians often underestimate environmental contributions. One might meticulously treat a patient's hypertension and cholesterol, but if that patient lives in an area with extremely high pollution or has unrecognized heavy metal exposure, their risk could remain elevated. This underscores the need for broader public health and policy interventions: **improving air quality, regulating emissions and industrial pollutants, and ensuring safe drinking water** could prevent millions of heart attacks and strokes. Encouragingly, some improvements have been documented; for example, after a coal-burning ban in Ireland, cardiovascular death rates declined measurably in subsequent years, and during the 2020 pandemic lockdowns (when air pollution temporarily plummeted), some regions saw short-term drops in heart attack admissions. On the clinical side, physicians should consider environmental risk assessment as part of routine care in certain situations (e.g. asking about occupational exposures, residence near highways or factories, use of well water, etc.). They might also advise mitigation strategies: for instance, indoor air purifiers for patients in polluted areas, consuming foods rich in antioxidants to combat oxidative stress, or chelation therapy in cases of documented heavy metal burden with cardiovascular implications.

In conclusion, environmental pollutants act as *causal* cardiovascular risk factors much like the traditional ones – and they are modifiable at both individual and societal levels. The data now support viewing **clean air and a toxin-free environment as vital components of cardiovascular health**. By addressing these non-traditional factors through policy (e.g. emissions standards, removing lead from products, banning harmful chemicals in consumer goods) and individual counseling (avoiding smoke, using water filters in high-arsenic areas, etc.), we can achieve further reductions in CVD incidence beyond what is possible by targeting traditional factors alone.

Conclusion

Modern cardiovascular medicine is expanding its focus to include a host of **emerging risk factors** beyond the classic Framingham triad of pressure, lipids, and smoking. Dental health, immune system activity, somatic mutations in blood cells, gut microbial metabolites, and environmental exposures all play meaningful roles in the development of heart disease. These factors are often interrelated with traditional risks – for example, chronic inflammation may

underlie diabetes or mediate the effects of obesity, and air pollution can worsen hypertension – but they also represent **independent pathways to pathology**. The unifying theme among many of these non-traditional risks is **inflammation and oxidative stress**: periodontal disease, autoimmune disorders, CHIP, TMAO/ImP, and pollutants all converge on activating inflammatory cascades that injure the endothelium and accelerate atherosclerosis. Recognizing these contributors is important for fully understanding an individual's risk and the residual risk that persists even after optimal control of blood pressure, glucose, and cholesterol.

From a comparative standpoint, some emerging factors (like air pollution or chronic inflammation) have effect sizes comparable to the "big" traditional factors, meaning they contribute to a substantial proportion of cardiac events. Others (like a single metabolite or a specific mutation) might confer a more moderate risk but could be crucial in certain subsets of patients. Importantly, all of these factors offer **new opportunities for intervention**. Just as the advent of statins and antihypertensives revolutionized risk reduction in the late 20th century, newer interventions might target these novel domains: anti-inflammatory drugs to neutralize cytokines, therapies to eradicate or suppress harmful clonal hematopoiesis, prebiotic/probiotic regimens or enzyme inhibitors to modulate the gut microbiome, and broad public health measures to reduce environmental toxin exposure. Indeed, some interventions (like IL-1β inhibitors or colchicine for inflammation) have already shown success in trials, and others (I1R blockers for ImP-driven disease, or metal chelation in select patients) are on the horizongenengnews.comprofessional.heart.org.

For clinicians and researchers, the task ahead is to integrate these emerging risk factors into a **holistic model of cardiovascular prevention**. Risk calculators may eventually incorporate biomarkers of inflammation (e.g. CRP), genetic screening for CHIP in older adults, or measures of environmental exposure for a more precise risk stratification. Multidisciplinary care – involving cardiologists, immunologists, dentists, endocrinologists, and environmental health experts – will be beneficial to address the multifactorial nature of heart disease. On a policy level, framing air pollution and toxic chemicals as cardiovascular risk factors strengthens the case for regulatory action as a means of heart disease preventionahajournals.org. At the patient level, lifestyle advice may broaden to include not just diet and exercise, but also oral hygiene, avoidance of polluted environments, and perhaps personalized nutrition to foster a heart-healthy microbiome.

In summary, as our scientific understanding deepens, it's clear that **cardiovascular risk is a tapestry woven from both traditional and non-traditional threads**. Tackling only the well-known factors leaves some threads – and thus some risk – unaddressed. By shining light on these emerging risk factors and aggressively intervening when possible, we move closer to the goal of comprehensively preventing heart disease. The continuing research into these areas holds great promise: it not only elucidates novel mechanisms of disease but also paves the way for innovative therapies that could further reduce the global burden of cardiovascular morbidity and mortality.

Sources: The information above is drawn from recent scientific literature and consensus reports, including studies on periodontal disease and CVD riskmdpi.commdpi.com, inflammatory

biomarkers and trials (Ridker *et al.*)frontiersin.orgfrontiersin.org, clonal hematopoiesis research in *JAMA/NEJM* and AHA statementsacc.orgacc.org, gut microbiome studies from Cleveland Clinic and othersfrontiersin.orggenengnews.com, and environmental health analyses (Global Burden of Disease, AHA Scientific Statements)ahajournals.orgprofessional.heart.orgmdpi.com. These sources collectively underscore the multifaceted nature of heart disease risk in the 21st century. Each risk factor discussed contributes to our evolving understanding of cardiovascular pathophysiology and opens new avenues for reducing risk beyond the traditional toolkit. By addressing both the old and the new risk factors, we can continue to make strides in preventing the world's leading cause of death.

The New Frontier of Cardiovascular Risk: An Integrated Analysis of Non-Traditional Pathogenic Factors

Introduction: Beyond Cholesterol—Understanding Residual Risk and the Centrality of Inflammation

Defining the Modern Landscape of Cardiovascular Risk

For decades, the clinical approach to preventing cardiovascular disease (CVD) has been anchored by a set of well-established, "traditional" risk factors: hypertension, dyslipidemia (abnormal cholesterol levels), diabetes mellitus, and smoking.[1] The identification and management of these factors have been cornerstones of public health, leading to significant reductions in CVD-related mortality. However, a persistent and clinically significant challenge remains: a substantial proportion of cardiovascular events, with some estimates as high as 50%, occur in individuals who do not present with a high burden of these traditional risk factors.[3] This phenomenon has given rise to the concept of "residual risk," the ongoing threat of a cardiovascular event that persists even after traditional risk factors, particularly

low-density lipoprotein (LDL) cholesterol, are aggressively managed.[5] The existence of this residual risk has catalyzed a paradigm shift in cardiology, compelling researchers and clinicians to look beyond conventional metrics and explore a new frontier of "non-traditional" risk factors that contribute to the pathogenesis of CVD.[7]

The Inflammation Hypothesis of Atherosclerosis

Central to understanding this new frontier is the recognition that atherosclerosis—the underlying pathology of most heart attacks and strokes—is not simply a plumbing problem of passive lipid deposition but is fundamentally a chronic inflammatory disease.[9] This "inflammation hypothesis" posits that the immune system plays a critical and active role at every stage of the disease, from the initial lesion to the final, catastrophic thrombotic event.[12] This framework is crucial because it provides a unifying biological pathway through which a diverse array of seemingly unrelated insults can promote vascular disease. Consequently, a key component of the aforementioned residual risk is now understood to be "residual inflammatory risk," a state of persistent, low-grade systemic inflammation that continues to drive atherogenesis even in patients with well-controlled cholesterol levels.[5]

A Unified Framework

This report provides an exhaustive analysis of five major non-traditional domains of cardiovascular risk: dental health (specifically periodontal disease), systemic immune activation, mutations in blood stem cells (Clonal Hematopoiesis of Indeterminate Potential and Myeloproliferative Neoplasms), the gut microbiome, and environmental pollutants. The primary thesis of this analysis is that these factors are best understood not as isolated phenomena but as distinct upstream triggers that converge on the common downstream pathway of chronic systemic inflammation and immune dysregulation. Each factor represents a unique origin story for the inflammatory cascade that ultimately injures the vasculature. Periodontal disease introduces a chronic infectious and inflammatory burden; clonal hematopoiesis generates genetically programmed pro-inflammatory leukocytes; gut dysbiosis produces circulating inflammatory metabolites; and environmental pollutants trigger a cascade of oxidative stress and inflammation. By examining these factors through the unifying lens of inflammation, a more cohesive and mechanistically sound picture of modern cardiovascular risk emerges.

Evaluating the Evidence

In exploring these novel risk factors, it is essential to maintain a critical perspective on the nature of the evidence. For many of these domains, the scientific literature is characterized by strong and consistent epidemiological associations from large-scale observational studies.[13] However, establishing definitive causality—proving that the factor itself directly causes the disease and that its modification prevents it—is a far greater challenge. This is often due to the presence of powerful confounding variables and the current lack of large, definitive randomized controlled trials (RCTs) for intervention.[13] Throughout this report, a careful distinction will be made between established causality, strong association, and emerging hypotheses, reflecting the dynamic and evolving state of knowledge in this field.[1]

Risk Factor	Primary Source/Origin	Key Pathogenic Mediators	Core Cardiovascular Mechanisms	Strength of Evidence (Association)
Dental Health (Periodontitis)	Chronic bacterial infection of the gums	*Porphyromonas gingivalis*, *Fusobacterium nucleatum*, Lipopolysaccharide (LPS), systemic cytokines (IL-6, TNF-α)	Systemic Inflammation, Endothelial Dysfunction, Direct Plaque Colonization	Strong, Consistent Association
Immune Activation	Response to endogenous/exogenous danger signals	Oxidized LDL, cholesterol crystals, cytokines (IL-1β, IL-6), hs-CRP	Innate/Adaptive Immune Cell Activation, Inflammasome Activation, Plaque Formation & Destabilization	Causal (Established)
Blood Stem Cell	Age-related somatic	**CHIP:** *TET2*, *DNMT3A*, *JAK2*	**CHIP:** Clonal expansion of	Strong, Potent Association

Mutations	mutations in hematopoietic stem cells	mutations; **MPN:** Abnormal blood cells	pro-inflammatory leukocytes; **MPN:** Pro-thrombotic state, hyperviscosity	(CHIP); Causal (MPN)
Gut Microbiome	Dysbiosis; Diet-microbe interactions	Metabolites: Trimethylamine N-oxide (TMAO), Imidazole Propionate (ImP)	Impaired Cholesterol Metabolism, Platelet Hyperreactivity, Endothelial Dysfunction, Receptor-Mediated Inflammation	Strong, Emerging Association
Environmental Pollutants	Inhalation/ingestion of environmental toxins	Particulate Matter (PM2.5), Heavy Metals (Lead, Cadmium)	Systemic Inflammation, Oxidative Stress, Autonomic Dysfunction, Direct Endothelial Toxicity	Strong, Causal (Air Pollution)

Section 1: The Oral-Systemic Connection: Periodontal Disease and Atherosclerosis

The concept that health within the oral cavity is intrinsically linked to the health of the entire body—the oral-systemic connection—has gained significant traction, with the association between periodontal disease and atherosclerotic cardiovascular disease being one of the most extensively studied examples.[17] Periodontal disease, a chronic inflammatory condition initiated by a dysbiotic bacterial film on the teeth, results in the progressive destruction of the tooth-supporting tissues.[19] Beyond its local effects, this condition serves as a persistent

reservoir of bacteria and inflammatory mediators that can gain access to the systemic circulation, thereby contributing to vascular pathology at distant sites.[21]

1.1. Pathophysiological Mechanisms: From Local Infection to Systemic Disease

The link between periodontal disease and atherosclerosis is supported by several plausible biological mechanisms that detail how a localized oral infection can initiate and exacerbate a systemic vascular disease. These mechanisms are not mutually exclusive and likely act in concert.

Bacteremia and Direct Vascular Invasion

Periodontal disease compromises the integrity of the gingival epithelium, creating an ulcerated surface that serves as a portal of entry for oral bacteria into the bloodstream.[17] Routine mechanical actions such as chewing, brushing, and dental procedures can induce transient bacteremia, releasing oral pathogens and their products into the circulation.[21] Key periodontal pathogens, including

Porphyromonas gingivalis (Pg), *Fusobacterium nucleatum* (Fn), and *Aggregatibacter actinomycetemcomitans* (Aa), have been identified. Evidence strongly suggests that this is not a benign, transient event. DNA from these specific oral pathogens has been detected directly within human atherosclerotic plaques and in thrombi recovered from patients experiencing acute myocardial infarction.[22] This indicates that these organisms can travel through the bloodstream, adhere to and invade the vascular endothelium, and colonize the atheroma itself. Once inside the vessel wall, these bacteria and their components, such as the potent endotoxin lipopolysaccharide (LPS) from Gram-negative bacteria like Pg, can incite a local inflammatory and immune response, directly contributing to plaque formation, progression, and instability.[22]

The Local-to-Systemic Inflammatory Cascade

Beyond direct bacterial invasion, the periodontal lesion itself functions as a factory for

pro-inflammatory mediators. The host's immune response to the chronic bacterial challenge in the gums leads to the local production of a host of inflammatory cytokines, including Interleukin-1β (IL-1β), Interleukin-6 (IL-6), and Tumor Necrosis Factor-alpha (TNF-α), as well as enzymes like matrix metalloproteinases (MMPs) that degrade tissue.[23] These locally produced mediators do not remain confined to the oral cavity. They "spill over" into the systemic circulation, elevating the body's overall inflammatory state.[13] This contributes to the chronic, low-grade systemic inflammation that is a well-established driver of all stages of atherogenesis.[23] Studies have demonstrated that individuals with periodontitis have elevated systemic levels of inflammatory markers like C-reactive protein (CRP) and fibrinogen, which decrease following successful periodontal therapy.[13] This provides a direct mechanistic link: the local inflammation in the gums fuels the systemic inflammation that damages arteries.

Immune Activation and Molecular Mimicry

The chronic presence of periodontal pathogens perpetually stimulates the host's immune system. Pathogens like *P. gingivalis* are potent activators of innate immune cells, such as macrophages, which are central players in atherosclerosis.[23] Furthermore, a concept known as molecular mimicry may play a role. Heat Shock Proteins (HSPs) produced by oral bacteria are structurally similar to human HSPs. The immune response mounted against the bacterial HSPs may cross-react with human HSPs expressed by endothelial cells under stress, leading to autoimmune-mediated vascular damage.[23] This chronic activation of both innate and adaptive immunity, driven by the persistent oral infection, adds to the systemic inflammatory burden and contributes to the autoimmune components of atherosclerosis.[23]

1.2. Evaluating the Epidemiological Evidence: A Critical Appraisal

The mechanistic plausibility of the oral-systemic link is supported by a large body of epidemiological research, though the interpretation of this evidence requires nuance.

Strength of Association

More than 50 prospective cohort and case-control studies have investigated the relationship between periodontal disease and CVD, with the majority finding a positive association.[13]

Several meta-analyses have synthesized this data, reporting statistically significant, albeit modest, increases in risk. For instance, after multivariable adjustment for some traditional risk factors, the odds ratio for a first myocardial infarction in individuals with periodontitis was found to be 1.28 (95% Confidence Interval, 1.03–1.60).[13] Another meta-analysis reported a similar odds ratio of 1.31 for the association between chronic periodontitis and coronary heart disease.[25] Systematic reviews have consistently concluded that periodontal disease is an independent risk factor or marker for coronary heart disease, with summary relative risk estimates ranging from 1.24 to 1.34.[24] This large and consistent body of observational evidence establishes a firm link between the two conditions.

The Causation Conundrum and Confounding Variables

Despite the strong association, proving that periodontal disease *causes* cardiovascular disease has been challenging.[13] A major issue is the presence of shared confounding variables. Lifestyle and systemic factors such as smoking, diabetes mellitus, older age, male sex, and lower socioeconomic status are potent risk factors for

both periodontal disease and CVD.[13] While many studies attempt to statistically adjust for these confounders, such adjustments are often imperfect, and unrecognized or unmeasured confounders may still exist.[13] The fact that the hazard ratios are modest (typically around 1.20 in adjusted models) suggests that while an independent causal link may exist, these shared risk factors are responsible for a substantial portion of the observed association.[13]

The Interventional Gap

The ultimate proof of causation would come from large-scale randomized controlled trials (RCTs) demonstrating that treating periodontal disease reduces the incidence of major adverse cardiovascular events (MACE). To date, such evidence is lacking.[13] The Periodontitis and Vascular Events (PAVE) pilot study, which compared scaling and root planing to community care in patients with stable coronary artery disease, was too small to be conclusive and did not show a reduction in cardiovascular events.[13] Due to this "interventional gap," major clinical guidelines from bodies like the American Heart Association do not currently recommend treating periodontal disease for the primary or secondary prevention of atherosclerotic CVD.[13] The relationship is acknowledged as an association, but causality remains unproven from an interventional standpoint.

1.3. Clinical Implications and Public Health Perspectives

Despite the unresolved issue of causality, the strong and consistent association between oral and cardiovascular health has significant clinical and public health implications.

The "Healthy Smiles, Healthy Hearts" Paradigm

Recognizing the powerful link, the American Heart Association (AHA), in collaboration with other organizations, has launched initiatives such as "Healthy Smiles, Healthy Hearts™".[27] This paradigm shifts the focus from proving causality to leveraging the association for practical public health benefit. The core insight is that the dental office represents a unique and often underutilized point of contact with the healthcare system. For millions of people, a visit to the dentist is their only regular interaction with a health professional.[27] This positions dental teams as essential frontline partners in the early detection of systemic diseases, including hypertension and other cardiovascular risk factors.[27]

Periodontitis as a Clinical Risk Marker

From a clinical perspective, the presence of moderate to severe periodontal disease should be viewed as a significant red flag for a patient's overall systemic health. It serves as a tangible, visible marker of a chronic inflammatory burden.[17] A patient with inflamed, bleeding gums likely has elevated systemic inflammation, which is detrimental to their vascular health, regardless of whether the periodontitis is the primary cause. Therefore, the detection of periodontal disease should prompt clinicians to conduct a more thorough cardiovascular risk assessment. Furthermore, integrating simple, non-invasive cardiovascular screenings, such as blood pressure measurement, into routine dental care is a low-cost, high-yield strategy to identify at-risk individuals who might otherwise be missed.[27] While treating gum disease may not have been definitively proven to prevent heart attacks, identifying and managing the shared risk factors (like smoking and diabetes) and the systemic conditions (like hypertension) that often accompany it undoubtedly will.[13]

Section 2: Systemic Inflammation and Immune Activation: The Inflammatory Heart of Cardiovascular Disease

The conceptualization of atherosclerosis has undergone a profound evolution, moving from a model of passive lipid accumulation to a dynamic and complex understanding of the disease as a chronic inflammatory process.[9] This paradigm shift places the immune system at the very center of the pathogenesis of cardiovascular disease. Systemic inflammation is no longer considered a mere bystander or a consequence of the disease but is now understood to be a fundamental driver at every stage, from the earliest fatty streak to the final thrombotic event.[12] This section will detail the cellular and molecular mechanisms of this inflammatory process and discuss the clinical utility of biomarkers used to measure this risk.

2.1. Atherosclerosis as a Chronic Inflammatory Disease: A Paradigm Shift

The atherosclerotic process is an intricate interplay between traditional risk factors, lipids, and a multi-stage immune response within the arterial wall.

Initiation: Endothelial Dysfunction and Lipid Infiltration

The process begins with an "injury" to the vascular endothelium, the single layer of cells lining the arteries. This injury is not necessarily physical but is a functional impairment caused by chronic exposure to risk factors such as hypertension, cigarette smoke, hyperglycemia, and, critically, elevated levels of atherogenic lipoproteins.[11] This leads to endothelial dysfunction, a state characterized by increased permeability and the expression of adhesion molecules on the cell surface.[11] The compromised endothelial barrier allows low-density lipoprotein (LDL) particles to move from the bloodstream into the subendothelial space, or intima, where they become trapped.[9]

Propagation: The Immune Response Cascade

Once trapped in the intima, LDL particles undergo oxidative modification, forming oxidized LDL (oxLDL).[9] The immune system recognizes oxLDL not as a native molecule but as a danger-associated molecular pattern (DAMP), akin to a signal from a damaged cell, triggering an innate immune response.[9] The activated endothelial cells express adhesion molecules that capture circulating monocytes. These monocytes then migrate into the intima, where they differentiate into macrophages.[12] Macrophages are voracious phagocytes, and they begin to engulf the abundant oxLDL via scavenger receptors. As they become engorged with lipids, they transform into "foam cells," the defining cellular component of the early atherosclerotic lesion known as the fatty streak.[9] This process involves both the innate and adaptive immune systems, with T-lymphocytes and other immune cells also being recruited to the growing lesion.[9]

Amplification via the Inflammasome

The inflammatory response is not static but is actively amplified within the plaque. As macrophages become overloaded with cholesterol, some of it forms microscopic intracellular cholesterol crystals.[9] These crystals are a powerful danger signal that directly activates a multiprotein complex within the macrophage called the "NOD-like" receptor family pyrin domain containing 3 (NLRP3) inflammasome.[5] The activated inflammasome functions as a molecular platform for the enzyme caspase-1, which cleaves pro-Interleukin-1β (pro-IL-1β) into its highly active, secreted form, IL-1β.[5] IL-1β is a master inflammatory cytokine that orchestrates a powerful downstream cascade. It stimulates the production of a host of other pro-inflammatory cytokines, such as Interleukin-6 (IL-6), and promotes further recruitment of immune cells to the plaque.[12] IL-6, in turn, travels to the liver and stimulates the production of acute-phase reactant proteins, most notably C-reactive protein (CRP), which can be measured in the blood as a systemic marker of this entire process.[9]

Plaque Destabilization and Thrombosis

This chronic, self-perpetuating inflammatory cycle leads to the development of a complex atherosclerotic plaque, characterized by a lipid-rich necrotic core containing dead foam cells and cellular debris, covered by a fibrous cap composed of smooth muscle cells and collagen.[12] The stability of this plaque is the key determinant of clinical outcomes. Within the plaque, activated inflammatory cells, particularly macrophages and mast cells, release enzymes called

matrix metalloproteinases (MMPs).[12] These enzymes degrade the collagen that provides structural integrity to the fibrous cap. A plaque with a high degree of inflammation, a large necrotic core, and a thin, degraded fibrous cap is termed a "vulnerable" or "unstable" plaque.[9] The physical stress of blood flow can cause this fragile cap to rupture or erode, exposing the highly thrombogenic contents of the necrotic core (such as tissue factor) to the circulating blood.[12] This exposure triggers a rapid cascade of platelet activation and coagulation, leading to the formation of an occlusive thrombus (blood clot). If this thrombus blocks an artery supplying the heart, it causes a myocardial infarction (heart attack); if it blocks an artery supplying the brain, it causes an ischemic stroke.[29] This final step demonstrates the critical link between chronic inflammation and acute thrombosis, an "Inflammatory-Thrombotic Axis" that underpins most major cardiovascular events.

2.2. Clinical Measurement of Inflammatory Risk: High-Sensitivity C-Reactive Protein (hs-CRP)

Given the central role of inflammation in atherosclerosis, identifying individuals with a heightened inflammatory state has become a key goal in cardiovascular risk prediction.

hs-CRP as a Predictive Biomarker

C-reactive protein (CRP) is an acute-phase protein synthesized by the liver primarily in response to stimulation by IL-6.[12] As such, its circulating level serves as a downstream indicator of the upstream IL-1β/IL-6 inflammatory axis that is active within atherosclerotic plaques.[12] High-sensitivity assays (hs-CRP) can accurately measure the very low levels of CRP that reflect chronic, subclinical vascular inflammation.[31] A vast body of evidence from large-scale, prospective epidemiological studies has consistently shown that elevated hs-CRP levels are a powerful and independent predictor of future cardiovascular events, including myocardial infarction, stroke, and cardiovascular death.[6] An hs-CRP level greater than 2.0 mg/L or 3.0 mg/L is associated with a higher risk of heart disease, and this predictive value holds true even among individuals with low or normal LDL cholesterol levels.[4] This demonstrates that inflammatory risk and cholesterol risk are distinct and additive contributors to a person's overall cardiovascular threat.

Clinical Utility and Limitations

The discovery of hs-CRP's predictive power has led to its inclusion in some clinical guidelines as a "risk enhancer" to help refine risk stratification, particularly in individuals deemed to be at intermediate risk based on traditional scoring systems.[16] However, the role of hs-CRP is not without controversy. It is crucial to understand that CRP is a

marker of inflammation, not a direct causal agent in atherogenesis.[30] While some studies suggest monomeric forms of CRP found in tissues may have pro-inflammatory effects, the circulating pentameric form measured by hs-CRP is largely considered an indicator of an underlying process.[5]

A primary limitation of hs-CRP is its lack of specificity. Any source of systemic inflammation, from an acute infection or injury to chronic conditions like rheumatoid arthritis or even poor gum health, can elevate hs-CRP levels.[31] This means a high reading does not definitively point to vascular inflammation. For this reason, and because of a lack of definitive trial evidence showing that treatment decisions based on hs-CRP levels lead to better outcomes, the U.S. Preventive Services Task Force (USPSTF) has concluded that the current evidence is insufficient to recommend for or against routine hs-CRP screening for CVD risk assessment in all asymptomatic adults.[1] Nonetheless, in clinical practice, a persistently elevated hs-CRP level in an otherwise healthy individual is a strong signal of an underlying inflammatory risk that warrants aggressive management of all other modifiable risk factors.

Section 3: The Aging Hematopoietic System: Clonal Hematopoiesis and Malignant Progression

Aging is the single most potent, non-modifiable risk factor for cardiovascular disease. While this has long been attributed to the cumulative lifetime exposure to traditional risk factors, recent discoveries in hematology and genetics have unveiled a novel and powerful biological mechanism that directly links the aging process to accelerated atherosclerosis: clonal hematopoiesis. This phenomenon, which begins as a pre-malignant condition, represents a new axis of cardiovascular risk originating from the bone marrow.

3.1. Clonal Hematopoiesis of Indeterminate Potential (CHIP): An Age-Related Inflammatory Driver

Definition and Genetic Basis

Throughout life, hematopoietic stem cells (HSCs) in the bone marrow acquire random somatic mutations during cell division.[39] Most of these mutations are harmless, but occasionally a mutation occurs in a specific leukemia-associated "driver" gene that confers a competitive growth advantage to the stem cell.[39] This mutant stem cell then outcompetes its normal counterparts, leading to the clonal expansion of a distinct population of blood cells (leukocytes, red cells, platelets) that all carry the same mutation.[40] When this clonal expansion is detected in the blood of an individual who does not have a diagnosable blood cancer or unexplained cytopenias, the condition is termed Clonal Hematopoiesis of Indeterminate Potential (CHIP).[42]

The formal definition of CHIP requires the presence of a somatic mutation in a known myeloid cancer-associated gene at a variant allele frequency (VAF) of at least 2%.[40] The most commonly mutated genes in CHIP are those involved in epigenetic regulation, primarily

DNMT3A (DNA Methyltransferase 3 Alpha), *TET2* (Ten-Eleven Translocation 2), and *ASXL1* (ASXL Transcriptional Regulator 1), followed by the signaling gene *JAK2* (Janus Kinase 2).[39] CHIP is a phenomenon strongly associated with aging. While rare in individuals under 40, its prevalence increases dramatically with age, affecting 10% to 20% of people over the age of 70.[40]

Cardiovascular Risk Profile

The initial interest in CHIP was as a pre-malignant state, as it confers an increased risk of progressing to a hematologic malignancy like myelodysplastic syndrome or acute myeloid leukemia. However, the rate of this progression is low, at approximately 0.5-1% per year.[42] The landmark discovery was that individuals with CHIP have a 40% increase in all-cause mortality, which is not primarily driven by cancer.[42] Instead, the excess mortality is largely attributable to cardiovascular disease. Epidemiological studies have established CHIP as a potent and independent cardiovascular risk factor, approximately doubling the risk for coronary heart disease and ischemic stroke, and worsening outcomes in patients with heart failure.[39] For any given person with CHIP, the absolute risk of suffering a fatal cardiovascular event is substantially greater than their risk of developing leukemia, fundamentally reframing CHIP as a

major cardiovascular condition.[42]

Mechanisms of Accelerated Atherosclerosis

Experimental studies have confirmed a causal link between CHIP mutations and atherosclerosis, with different genes driving the disease through distinct but related inflammatory pathways.

- ***TET2* and *DNMT3A* Mutations:** These two mutations are the most prevalent in CHIP. While the genes have opposing biochemical functions in DNA methylation—*DNMT3A* adds methyl groups and *TET2* initiates their removal—loss-of-function mutations in either gene paradoxically converge on a common cellular outcome: they create pro-inflammatory macrophages.[45] In mouse models of atherosclerosis, bone marrow cells with *TET2* or *DNMT3A* mutations give rise to macrophages that exhibit a hyper-inflammatory response. Specifically, these mutant macrophages show heightened activation of the NLRP3 inflammasome, leading to increased production and secretion of the key atherogenic cytokines IL-1β and IL-6.[42] This genetically programmed increase in the inflammatory output of immune cells directly accelerates the development of atherosclerotic plaques.[42]
- ***JAK2* Mutations:** The *JAK2* V617F mutation is less common in CHIP but confers the highest magnitude of cardiovascular risk among the major driver genes.[39] It promotes atherothrombosis through mechanisms that are particularly relevant to acute events. Leukocytes carrying the *JAK2* V617F mutation are primed to form neutrophil extracellular traps (NETs)—web-like structures of DNA and proteins extruded by neutrophils that are highly pro-thrombotic.[42] Furthermore, *JAK2* V617F mutant macrophages are less efficient at clearing dead cells (a process called efferocytosis), which leads to the expansion of the unstable, lipid-rich necrotic core within atherosclerotic plaques.[42] Thus, *JAK2*-driven CHIP increases risk by both promoting thrombosis and creating more vulnerable plaques.

CHIP as a Mechanism of "Inflamm-Aging"

The discovery of CHIP provides a powerful molecular explanation for a portion of the age-related increase in cardiovascular risk. The term "inflamm-aging" describes the chronic,

sterile, low-grade inflammation that characterizes the aging process and is thought to contribute to a wide range of age-related diseases, including CVD.[11] CHIP is a tangible biological mechanism that drives inflamm-aging. As individuals age, the probability of acquiring and clonally expanding a CHIP mutation increases. The resulting expansion of a pro-inflammatory leukocyte population provides a persistent, endogenous source of inflammatory cytokines, effectively raising the body's baseline inflammatory state.[52] This age-acquired genetic alteration thus serves as a direct link between the aging process, chronic inflammation, and accelerated atherosclerosis.

3.2. Myeloproliferative Neoplasms (MPNs): The Malignant Continuum and Thrombotic Risk

From CHIP to MPN

Myeloproliferative Neoplasms (MPNs) are a group of chronic blood cancers that represent the malignant end of the clonal hematopoiesis spectrum. In MPNs—which include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (MF)—the clonal expansion of a mutated HSC is no longer occult but leads to the overproduction of one or more types of mature blood cells, resulting in overtly abnormal blood counts.[55] The same driver mutations found in CHIP, particularly

JAK2 V617F, are frequently the cause of MPNs.[57]

The Central Role of Thrombosis

While atherosclerosis is a concern, the paramount cardiovascular risk in patients with MPNs is thrombosis.[55] MPNs create a potent pro-thrombotic state that increases the risk of both arterial clots (leading to heart attack and stroke) and venous clots (leading to deep vein thrombosis, pulmonary embolism, and unusual clots in abdominal veins).[53] This heightened thrombotic risk is a multifactorial problem stemming directly from the consequences of the disease:

- **Abnormal Blood Cell Counts:** In PV, the marked excess of red blood cells increases

whole blood viscosity, making the blood "thicker" and more prone to clotting.[56] In ET, a very high platelet count (thrombocytosis) increases the raw material for clot formation.[56]

- **Cellular Hyperactivation:** The problem extends beyond mere numbers. The platelets and neutrophils produced by the malignant clone are intrinsically hyperactive. They are more "sticky" and more easily activated to initiate thrombosis.[53] As in CHIP, neutrophils from MPN patients show an increased tendency to form pro-thrombotic NETs.[53]
- **Systemic Inflammation:** MPNs are inflammatory diseases characterized by the overproduction of inflammatory cytokines, driven by the dysregulated signaling from mutations like *JAK2* V617F.[53] This systemic inflammation further contributes to endothelial dysfunction and a hypercoagulable state.

The clinical management of cardiovascular risk in MPN patients, therefore, focuses heavily on mitigating this thrombotic threat through therapies aimed at controlling blood cell counts (cytoreduction) and the use of antiplatelet agents (like aspirin) or anticoagulants ("blood thinners").[58]

Section 4: The Gut-Heart Axis: Microbial Metabolites as Drivers of Vascular Disease

The human gastrointestinal tract is home to trillions of microorganisms, collectively known as the gut microbiota. Far from being passive inhabitants, this complex ecosystem functions as a highly active "metabolic organ" that plays a profound role in host physiology, immunity, and, as is now increasingly clear, cardiovascular health.[2] The bidirectional communication between the gut and the heart, termed the "gut-heart axis," is mediated in large part by bioactive metabolites produced by the microbiota. These molecules can enter the systemic circulation and directly influence the pathogenesis of atherosclerosis and heart failure.[62]

4.1. Gut Dysbiosis, Intestinal Permeability, and Systemic Inflammation

A healthy gut microbiota is characterized by high diversity and a balance between beneficial and potentially harmful bacteria. An imbalance in this community, a state known as "dysbiosis," is associated with numerous disease states, including CVD.[64] One of the key consequences of dysbiosis is the impairment of the intestinal epithelial barrier function, leading to increased intestinal permeability, or "leaky gut".[62] This compromised barrier allows microbial components, most notably lipopolysaccharide (LPS) from the outer membrane of

Gram-negative bacteria, to translocate from the gut lumen into the systemic circulation.[2] Circulating LPS is a potent inflammatory trigger that binds to Toll-like receptor 4 (TLR4) on host immune cells, activating pro-inflammatory signaling pathways like NF-κB and contributing to the low-grade systemic inflammation that underpins atherosclerosis.[66]

4.2. Key Microbial Metabolites Driving Cardiovascular Risk

Beyond the general inflammatory effects of dysbiosis, specific metabolites produced by the gut microbiota from the digestion of dietary components have been identified as direct drivers of cardiovascular risk. This highlights a critical pathway where diet, microbial ecology, and host metabolism intersect to promote disease.

Trimethylamine N-oxide (TMAO)

- **Metabolic Pathway:** Trimethylamine N-oxide (TMAO) is a quintessential "meta-organismal" metabolite, meaning its production requires contributions from both the microbiota and the host.[67] The process begins with the ingestion of certain dietary nutrients, particularly choline, phosphatidylcholine, and L-carnitine, which are abundant in red meat, eggs, and fish.[68] Specific species of gut bacteria possess enzymes (e.g., choline TMA-lyase) that metabolize these precursors into the gas trimethylamine (TMA).[66] TMA is absorbed from the gut into the portal circulation and transported to the liver. There, the host enzyme Flavin-containing Monooxygenase 3 (FMO3) oxidizes TMA into TMAO, which is then released into the systemic circulation.[67]
- **Pro-Atherogenic Mechanisms:** A large body of clinical evidence has linked elevated circulating levels of TMAO with an increased risk of major adverse cardiovascular events (MACE), including heart attack, stroke, and death.[63] Experimental studies have elucidated several mechanisms by which TMAO promotes atherosclerosis and thrombosis [68]:
    1. **Altered Cholesterol Metabolism:** TMAO disrupts cholesterol homeostasis. It inhibits reverse cholesterol transport (RCT), the process by which excess cholesterol is removed from peripheral cells (like macrophages in the artery wall) and returned to the liver for excretion.[68] Simultaneously, it upregulates the expression of scavenger receptors (such as CD36 and SR-A1) on macrophages, increasing their uptake of LDL cholesterol.[68] This dual effect—impaired efflux and enhanced influx—promotes the transformation of macrophages into lipid-laden foam cells, the foundational step of atherosclerosis.[71]
    2. **Vascular Inflammation and Endothelial Dysfunction:** TMAO promotes a

pro-inflammatory state in the vasculature. It activates inflammatory signaling pathways like NF-κB in endothelial cells, leading to the expression of adhesion molecules that recruit inflammatory leukocytes to the vessel wall.[67] It also induces oxidative stress, which reduces the bioavailability of the critical vasodilator nitric oxide (NO), causing endothelial dysfunction.[71]

3. **Enhanced Thrombosis Risk:** TMAO directly impacts platelets, the key cells involved in blood clotting. It enhances platelet hyperreactivity by augmenting calcium signaling within the platelet, making them more prone to aggregation and thrombosis in response to stimuli.[68] This provides a direct link between this gut-derived metabolite and the risk of an acute thrombotic event.

- **Causality vs. Marker:** While the mechanistic evidence is compelling, there is an ongoing scientific debate regarding TMAO's role. Because TMAO is primarily cleared by the kidneys, elevated levels can be a marker of impaired renal function, itself a strong CVD risk factor. Some studies have found that the association between TMAO and cardiovascular events is weakened or eliminated after adjusting for kidney function.[72] Furthermore, high TMAO levels may simply be a marker of a diet rich in red meat and fat, which is independently associated with CVD risk. Thus, whether TMAO is a direct causal driver, a biomarker of a poor diet and kidney function, or a combination of both remains an active area of investigation.

Imidazole Propionate (ImP)

- **Metabolic Pathway:** Imidazole propionate (ImP) is another gut microbial metabolite, produced from the bacterial breakdown of the dietary amino acid histidine, a component of proteins.[75] Unlike TMAO, it does not require further conversion by the host to become active.[78]
- **Novel Pro-Atherogenic Mechanism:** Initially linked to type 2 diabetes and insulin resistance, very recent and groundbreaking research has identified ImP as a direct, causal driver of atherosclerosis through a novel mechanism.[75] Studies in animal models have shown that administering ImP directly accelerates the formation of arterial plaques.[78] The mechanism is distinct from traditional risk pathways and is notably *independent of cholesterol levels*.[77] ImP exerts its effect by binding to and activating the imidazoline-1 receptor (I1R) on immune cells.[78] This receptor activation triggers the mTORC1 signaling pathway, a central regulator of cell growth and metabolism, leading to a potent pro-inflammatory response within the arterial wall and promoting plaque development.[79] The discovery that blocking the I1R receptor can prevent this plaque formation, even in the presence of a high-cholesterol diet, opens up an entirely new therapeutic avenue for treating atherosclerosis.[78]

4.3. The Gut Microbiome as a "Metabolic Inflammatory Signature"

The roles of TMAO and ImP exemplify how the body is not a passive recipient of dietary risk but an active participant in its creation. The gut microbiome acts as a critical bioreactor or "metabolic transducer," converting external dietary inputs into a specific internal language of pathogenic signals that the cardiovascular system understands and responds to pathologically.[62] The composition of an individual's gut microbiota determines which metabolites are produced from their diet, creating a unique "metabolic inflammatory signature" that contributes to their overall cardiovascular risk profile.[65] This provides a powerful molecular explanation for how dietary patterns can influence cardiovascular health beyond their simple caloric or macronutrient content and underscores the potential of modulating the gut microbiome—through diet, prebiotics, or probiotics—as a future strategy for cardiovascular prevention.[65]

Metabolite	Dietary Precursor(s)	Microbial Conversion	Host Conversion	Pro-Atherogenic Mechanisms	Therapeutic Target?
Trimethylamine N-oxide (TMAO)	Choline, L-Carnitine (Red Meat, Eggs, Fish)	Precursor -> Trimethylamine (TMA) by gut microbial enzymes (e.g., CutC/D)	TMA -> TMAO in the liver by Flavin Monooxygenase 3 (FMO3)	• Inhibits Reverse Cholesterol Transport • Promotes Macrophage Foam Cell Formation • Induces Endothelial Dysfunction & Inflammation • Enhances Platelet Hyperreactivity & Thrombosis	Yes (e.g., FMO3 inhibition, microbial enzyme inhibition, dietary modification)

				Risk	
Imidazole Propionate (ImP)	Histidine (Various Proteins)	Histidine -> ImP by gut microbial enzymes	None (Directly active)	• Activates Imidazoline -1 Receptor (I1R) on immune cells • Triggers mTORC1 signaling pathway • Induces potent inflammation independent of cholesterol	Yes (e.g., I1R blockade, dietary modification)

Section 5: The Environmental Burden: Pollutants and Vascular Injury

While individual behaviors and genetics are major determinants of cardiovascular health, it is now unequivocally clear that the external environment plays a significant role. Exposure to environmental pollutants, including ambient air pollution and heavy metals, constitutes a potent and often unavoidable risk factor for cardiovascular disease.[84] These toxicants exert their effects through a variety of mechanisms that converge on the familiar pathways of inflammation, oxidative stress, and direct vascular injury, contributing substantially to the global burden of CVD.[87]

5.1. Air Pollution: An Established Environmental Cardiovascular Risk Factor

The Impact of Particulate Matter (PM2.5)

Among environmental pollutants, the link between fine particulate matter air pollution (particles with a diameter of 2.5 micrometers or less, or PM2.5) and cardiovascular disease is the most robust and well-established.[88] Generated from sources like vehicle exhaust, industrial emissions, power generation, and wildfire smoke, these tiny particles can be inhaled deep into the lungs.[90] A vast body of epidemiological evidence demonstrates that both short-term (hours to days) and long-term (years) exposure to elevated

PM2.5 levels are associated with increased cardiovascular morbidity and mortality.[84] Short-term exposure can trigger acute events like myocardial infarction, stroke, and arrhythmias, while long-term exposure accelerates the underlying process of atherosclerosis.[89]

The Triad of Pathophysiological Mechanisms

The systemic cardiovascular effects of inhaled particulate matter are not confined to the lungs. They are mediated by three primary and interconnected pathways that translate a respiratory exposure into a systemic vascular disease [93]:

1. **Pulmonary Inflammation and Systemic Spillover:** This is considered the dominant pathway. When PM2.5 particles are deposited in the alveoli, they are recognized as foreign invaders by lung-resident immune cells, particularly alveolar macrophages. This triggers a potent local inflammatory response, characterized by the production of reactive oxygen species (ROS) and the release of pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α.[93] These inflammatory mediators then "spill over" from the lungs into the systemic circulation. This systemic wave of inflammation promotes widespread endothelial dysfunction, increases blood coagulability (a pro-thrombotic state), and accelerates atherosclerotic plaque development throughout the body.[93]
2. **Direct Translocation:** The smallest particles, known as ultrafine particles (UFPs), are thought to be capable of penetrating the alveolar-capillary barrier and translocating directly from the lungs into the bloodstream.[92] Once in the circulation, these particles can travel to distant sites and exert direct toxic effects on the heart and blood vessels, promoting inflammation and oxidative stress at the site of the atherosclerotic plaque itself.[93]
3. **Autonomic Nervous System Dysfunction:** Inhaled particles can stimulate sensory nerve receptors in the airways. This can lead to an imbalance in the autonomic nervous

system (ANS), with a shift towards increased sympathetic nervous system activity.[93] This sympathetic activation can acutely increase heart rate, elevate blood pressure, and increase the risk of cardiac arrhythmias, providing a mechanism for how pollution exposure can trigger immediate cardiovascular events.[93]

5.2. Heavy Metal Toxicity: The Cardiovascular Impact of Lead and Cadmium

Beyond air pollution, chronic exposure to toxic heavy metals, even at low environmental levels, is an emerging risk factor for CVD.

Mechanisms of Cadmium-Induced Injury

Cadmium is a widespread environmental contaminant found in industrial emissions, tobacco smoke, and some foods. Chronic exposure is associated with hypertension, atherosclerosis, and heart failure.[96] Its cardiovascular toxicity is mediated by several mechanisms:

- **Oxidative Stress:** Cadmium is a potent inducer of oxidative stress, generating high levels of ROS that damage cellular components and disrupt the body's antioxidant defense systems.[96]
- **Direct Endothelial Toxicity:** Cadmium can directly injure and kill endothelial cells, compromising the integrity of the vascular barrier. This allows for the infiltration of lipids and inflammatory cells into the vessel wall, initiating the atherosclerotic process.[96]
- **Inflammation:** Cadmium exposure stimulates the release of pro-inflammatory cytokines, including IL-6 and TNF-α, contributing to the inflammatory milieu of atherosclerosis.[97]
- **Disruption of Ion Homeostasis:** Cadmium can interfere with cellular calcium signaling in vascular smooth muscle cells, which can alter vascular tone and promote hypertension.[96]

Mechanisms of Lead-Induced Injury

Lead is another ubiquitous environmental toxin, and chronic low-level exposure is a well-established cause of hypertension and cardiovascular disease.[101] Lead's vascular toxicity is extensive and multifaceted:

- **Impairment of Nitric Oxide (NO) Signaling:** Lead's primary mechanism for inducing hypertension is its devastating effect on the nitric oxide system. By promoting profound oxidative stress, lead leads to the rapid inactivation of NO, a critical molecule for vasodilation and endothelial health. This functional NO deficiency leads to vasoconstriction and elevated blood pressure.[101]
- **Systemic Effects:** Lead also augments sympathetic nervous system activity, increases the production of the potent vasoconstrictor endothelin, and alters the renin-angiotensin system, all of which contribute to hypertension.[101]
- **Vascular Remodeling:** In addition to its effects on vascular tone, lead directly injures the endothelium, impairs its ability to repair itself, and stimulates the proliferation of vascular smooth muscle cells, promoting the structural changes of arteriosclerosis (arterial stiffening).[102]

5.3. The "Inescapable Inflammatory Exposome"

The various environmental pollutants do not act in isolation. They are components of a broader "exposome"—the totality of environmental exposures an individual encounters throughout their life.[87] This concept reframes environmental risk not as a series of discrete encounters but as a continuous, low-level inflammatory and oxidative stress burden that is largely inescapable for many populations.[2] The lungs and gut act as transducers, converting these external environmental inputs into a common internal language of pathogenic signals—systemic inflammation and oxidative stress—that the cardiovascular system responds to over time with the development of disease.[85] This underscores the inextricable link between environmental policy, public health, and cardiovascular disease prevention, highlighting that individual health is deeply embedded within the health of the surrounding environment.

Conclusion: Synthesizing the New Frontier of Cardiovascular Risk

Recapitulation of a Unified Pathophysiology

The comprehensive analysis of these five non-traditional domains of cardiovascular risk reveals a remarkable convergence of pathophysiology. While their origins are disparate—a bacterial infection in the mouth, an age-related mutation in the bone marrow, a metabolic byproduct from the gut, or an inhaled particle from the environment—their paths ultimately lead to a common nexus of biological processes. Each of these factors was shown to initiate or amplify chronic systemic inflammation, induce oxidative stress, cause endothelial dysfunction, and promote a pro-thrombotic state. This demonstrates that the cardiovascular system responds to a wide variety of chronic insults with a stereotyped, and ultimately maladaptive, inflammatory and immune response that culminates in atherosclerosis and its clinical consequences.

The Overarching Role of Inflammation

This report's central and recurring theme is the confirmation of the inflammation hypothesis of atherosclerosis as the unifying framework for understanding modern cardiovascular risk. The future of cardiovascular risk assessment and prevention will increasingly depend on our ability to identify and mitigate the diverse triggers of this chronic inflammatory state. The concept of "residual risk" is, in large part, a reflection of this residual inflammatory risk. As therapies for traditional factors like LDL cholesterol become increasingly effective, the relative importance of these non-traditional inflammatory drivers will only grow.

Implications for Clinical Practice

The findings presented herein have profound implications for clinical practice, advocating for a more integrated and holistic approach to patient evaluation. The traditional, siloed assessment of cardiovascular risk must be expanded. A clinician aiming for a comprehensive understanding of a patient's true risk profile should consider:

- **Oral Health:** Is there evidence of periodontal disease, a visible sign of a chronic inflammatory burden?
- **Inflammatory State:** What is the patient's baseline level of systemic inflammation, as potentially measured by biomarkers like hs-CRP?
- **Age-Related Biology:** In an older patient with accelerated or unexplained atherosclerosis, could an underlying clonal hematopoietic process like CHIP be a contributing factor?
- **Diet and Gut Health:** Beyond simple dietary advice, is there a role for understanding the patient's gut microbial signature and its metabolic output?

- **Environmental Context:** What are the patient's occupational and residential exposures to air pollution and other environmental toxins?

By integrating these domains, clinicians can move beyond simplistic risk scores and build a more complete, personalized picture of an individual's journey toward cardiovascular disease.[7]

Future Directions: The Promise of Precision Prevention

The elucidation of these novel pathways does more than just expand our list of risk factors; it unveils a wealth of new therapeutic targets, heralding an era of precision prevention. The future of cardiovascular medicine may include:

- **Targeted Anti-Inflammatory Therapies:** The success of canakinumab, an IL-1β inhibitor, in the CANTOS trial provided proof-of-concept that targeting specific inflammatory pathways can reduce cardiovascular events.[6] Future therapies may target other key nodes like the NLRP3 inflammasome, particularly in high-risk populations such as those with CHIP.[50]
- **Microbiome Modulation:** The identification of specific pathogenic metabolites like TMAO and ImP opens the door to highly targeted interventions. These could include dietary modifications to limit precursor intake, the use of prebiotics or probiotics to shift the microbial community, or even drugs that inhibit the specific microbial or host enzymes responsible for their production.[69]
- **Public Health and Environmental Policy:** Perhaps most importantly, the strong evidence linking environmental pollutants to CVD underscores that cardiovascular prevention is not solely the responsibility of clinicians and patients. It is a societal responsibility. Public health policies aimed at reducing air pollution, ensuring clean water, and mitigating exposure to toxic metals are, in effect, large-scale cardiovascular prevention strategies.[87]

In conclusion, the frontier of cardiovascular risk is expanding rapidly. By embracing the complexity of these non-traditional factors and understanding their convergence on the central pathway of inflammation, we can develop more sophisticated strategies for risk prediction and forge new, more effective pathways for the prevention of cardiovascular disease.

Works cited

1. Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors - U.S. Preventive Services Task Force, accessed August 29, 2025, https://www.uspreventiveservicestaskforce.org/uspstf_admin/home/getfilebyid/3467

2. Non-Traditional Risk Factors as Contributors to Cardiovascular Disease - PMC, accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11273054/
3. (PDF) Cardiovascular diseases: Traditional and non-traditional risk ..., accessed August 29, 2025, https://www.researchgate.net/publication/306086376_Cardiovascular_diseases_Traditional_and_non-traditional_risk_factors
4. Inflammation marker can help identify heart risk in women without traditional factors, accessed August 29, 2025, https://www.news-medical.net/news/20250829/Inflammation-marker-can-help-identify-heart-risk-in-women-without-traditional-factors.aspx
5. Monomeric C-Reactive Protein in Atherosclerotic Cardiovascular Disease: Advances and Perspectives - MDPI, accessed August 29, 2025, https://www.mdpi.com/1422-0067/24/3/2079
6. Inflammation and Cardiovascular Disease: The Future - European Cardiology Review, accessed August 29, 2025, https://www.ecrjournal.com/articles/inflammation-and-cardiovascular-disease-future?language_content_entity=en
7. Non-Traditional Cardiovascular Risk Factors: Tailored Assessment and Clinical Implications, accessed August 29, 2025, https://www.mdpi.com/2308-3425/12/5/171
8. (PDF) Non-Traditional Cardiovascular Risk Factors: Tailored Assessment and Clinical Implications - ResearchGate, accessed August 29, 2025, https://www.researchgate.net/publication/391231987_Non-Traditional_Cardiovascular_Risk_Factors_Tailored_Assessment_and_Clinical_Implications
9. Immunity and Inflammation in Atherosclerosis | Circulation Research, accessed August 29, 2025, https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.118.313591
10. Atherosclerosis: A Chronic Inflammatory Disease with an ..., accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6298754/
11. The Role of Inflammation in Cardiovascular Disease - MDPI, accessed August 29, 2025, https://www.mdpi.com/1422-0067/23/21/12906
12. Inflammation as a Cardiovascular Risk Factor - American Heart Association Journals, accessed August 29, 2025, https://www.ahajournals.org/doi/10.1161/01.cir.0000129535.04194.38
13. Increasing Evidence for an Association Between Periodontitis and Cardiovascular Disease | Circulation, accessed August 29, 2025, https://www.ahajournals.org/doi/10.1161/circulationaha.115.020869
14. Using Nontraditional Risk Factors in Coronary Heart Disease Risk Assessment: U.S. Preventive Services Task Force Recommendation Statement | Annals of Internal Medicine - ACP Journals, accessed August 29, 2025, https://www.acpjournals.org/doi/10.7326/0003-4819-151-7-200910060-00008
15. Risk Assessment for Cardiovascular Disease with Nontraditional Risk Factors: Recommendation Statement | AAFP, accessed August 29, 2025, https://www.aafp.org/pubs/afp/issues/2019/0115/od1.html
16. Recommendation: Cardiovascular Disease: Risk Assessment With Nontraditional Risk Factors | United States Preventive Services Taskforce, accessed August 29,

2025, https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/cardiovascular-disease-screening-using-nontraditional-risk-assessment
17. Exploring the Link Between Oral Health and Heart Disease - Tulsa Precision Dental, accessed August 29, 2025, https://tulsaprecisiondental.com/exploring-the-link-between-oral-health-and-heart-disease/
18. Oral health as a modifiable risk factor for cardiovascular diseases - PubMed, accessed August 29, 2025, https://pubmed.ncbi.nlm.nih.gov/36963476/
19. Periodontal disease is associated with the risk of cardiovascular disease independent of sex: A meta-analysis - Frontiers, accessed August 29, 2025, https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2023.1114927/full
20. Periodontitis is associated with hypertension: a systematic review and meta-analysis | Cardiovascular Research | Oxford Academic, accessed August 29, 2025, https://academic.oup.com/cardiovascres/article/116/1/28/5572510
21. Oral Bacteria Create Risks: Heart Diseases, Diabetes, Dementia - Washington Center for Dentistry, accessed August 29, 2025, https://washdent.com/oral-health-and-heart-risks/oral-bacteria-create-risk-in-many-areas
22. MECHANISMS INVOLVED IN THE ASSOCIATION BETWEEN ..., accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3373016/
23. Oral health and atherosclerotic cardiovascular disease: A review ..., accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8387275/
24. Periodontal Disease and Coronary Heart Disease Incidence: A Systematic Review and Meta-analysis - PMC, accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2596495/
25. CORRELATION BETWEEN CHRONIC PERIODONTITIS AND CARDIOVASCULAR DISEASES: A SYSTEMATIC REVIEW | Heart, accessed August 29, 2025, https://heart.bmj.com/content/98/Suppl_2/E93.4
26. Heart Disease and Oral Health - MouthHealthy, accessed August 29, 2025, https://www.mouthhealthy.org/all-topics-a-z/heart-disease-and-oral-health
27. About Healthy Smiles Healthy Hearts | American Heart Association, accessed August 29, 2025, https://www.heart.org/en/health-topics/oral-health/about-healthy-smiles-healthy-hearts
28. Dental Management Considerations for Patients with Cardiovascular Disease—A Narrative Review - PMC, accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11266964/
29. Inflammation and Heart Disease | American Heart Association, accessed August 29, 2025, https://www.heart.org/en/health-topics/consumer-healthcare/what-is-cardiovascular-disease/inflammation-and-heart-disease
30. C-reactive protein in atherosclerosis: A causal factor? - Oxford Academic, accessed August 29, 2025,

https://academic.oup.com/cardiovascres/article/71/1/30/269442
31. C-reactive protein test - Mayo Clinic, accessed August 29, 2025, https://www.mayoclinic.org/tests-procedures/c-reactive-protein-test/about/pac-20385228
32. The connection between C-reactive protein and atherosclerosis - PMC, accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3364506/
33. High-sensitivity C-reactive Protein in Atherosclerotic Cardiovascular Disease: To Measure or Not to Measure? - US Cardiology Review, accessed August 29, 2025, https://www.uscjournal.com/articles/high-sensitivity-c-reactive-protein-atherosclerotic-cardiovascular-disease-measure-or-not?language_content_entity=en
34. Inflammation, Infection, and Cardiovascular Risk | Circulation - American Heart Association Journals, accessed August 29, 2025, https://www.ahajournals.org/doi/10.1161/01.CIR.97.17.1671
35. C-reactive protein and cardiovascular risk among women with no standard modifiable risk factors: evaluating the 'SMuRF-less but inflamed' | European Heart Journal | Oxford Academic, accessed August 29, 2025, https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaf658/8242429
36. What does a high C-reactive protein (CRP) level in the body mean, what is the impact on life span and how to lower it, accessed August 29, 2025, https://timesofindia.indiatimes.com/life-style/health-fitness/health-news/what-does-a-high-c-reactive-protein-crp-level-in-the-body-mean-how-does-it-affect-us-and-how-can-we-lower-it/articleshow/123524022.cms
37. C-Reactive Protein in Atherothrombosis and Angiogenesis - Frontiers, accessed August 29, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2018.00430/full
38. C-Reactive Protein in Atherosclerosis—More than a Biomarker, but not Just a Culprit - PMC, accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11262456/
39. Clonal Hematopoiesis: The Emergent CVD Risk Factor ..., accessed August 29, 2025, https://www.ahajournals.org/doi/10.1161/ATVBAHA.123.319562
40. Clonal hematopoiesis and atherosclerotic cardiovascular disease: A primer | Clínica e Investigación en Arteriosclerosis (English Edition) - Elsevier, accessed August 29, 2025, https://www.elsevier.es/en-revista-clinica-e-investigacion-arteriosclerosis-english-415-articulo-clonal-hematopoiesis-atherosclerotic-cardiovascular-disease-S2529912323000104
41. Clonal hematopoiesis and atherosclerotic cardiovascular disease: A primer - Elsevier, accessed August 29, 2025, https://www.elsevier.es/es-revista-clinica-e-investigacion-arteriosclerosis-15-articulo-clonal-hematopoiesis-atherosclerotic-cardiovascular-disease-S021491682100139X
42. Clonal Hematopoiesis at Crossroads of Aging, Cardiovascular ..., accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6681657/

43. Biomarkers in clonal haematopoiesis of indeterminate potential (CHIP) linking cardiovascular diseases, myeloid neoplasms and inflammation - PMC - PubMed Central, accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12031762/
44. Clonal hematopoiesis and atherosclerosis - JCI, accessed August 29, 2025, https://www.jci.org/articles/view/180066
45. Clonal Hematopoiesis and Inflammation - College of American Pathologists, accessed August 29, 2025, https://www.cap.org/member-resources/articles/chipping-at-inflammation
46. Translating Evidence from Clonal Hematopoiesis to Cardiovascular ..., accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7465104/
47. Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Disease - eScholarship, accessed August 29, 2025, https://escholarship.org/content/qt1zx5h72x/qt1zx5h72x_noSplash_39b377e969be715719ce88b2e54792f5.pdf?t=qd8r68
48. Association of clonal hematopoiesis mutations with clinical outcomes: A systematic review and meta-analysis - PubMed, accessed August 29, 2025, https://pubmed.ncbi.nlm.nih.gov/35015316/
49. CHIP and cardiovascular disease | Institute for Stem Cell Biology ..., accessed August 29, 2025, https://med.stanford.edu/stemcell/news/iscbrmarticles/chip-and-cardiovascular-disease.html
50. Clonal Hematopoiesis of Indeterminate Potential From a Heart Failure Specialist's Point of View, accessed August 29, 2025, https://www.ahajournals.org/doi/10.1161/JAHA.123.030603
51. Targeting Inflammation and Clonal Hematopoiesis to Mitigate ASCVD: Current Endeavors and Future Opportunities - American College of Cardiology, accessed August 29, 2025, https://www.acc.org/Latest-in-Cardiology/Articles/2024/01/08/12/37/Targeting-Inflammation-and-Clonal-Hematopoiesis-to-Mitigate-ASCVD
52. Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease - PMC - PubMed Central, accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9448847/
53. Cardiovascular Disease in Myeloproliferative Neoplasms: JACC: CardioOncology State-of-the-Art Review - PMC - PubMed Central, accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9270630/
54. pmc.ncbi.nlm.nih.gov, accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7104598/#:~:text=In%20the%20setting%20of%20clonal,injury%20processes%2C%20driving%20disease%20progression.
55. Heart Problems and MPNs: Are They Connected? - myMPNteam, accessed August 29, 2025, https://www.mympnteam.com/resources/heart-problems-and-mpns-are-they-connected
56. Myeloproliferative Neoplasm: Symptoms, Types & Treatment - Cleveland Clinic,

accessed August 29, 2025, https://my.clevelandclinic.org/health/diseases/24144-myeloproliferative-neoplasms
57. Cardiovascular Risk and MPNs - MPN Research Foundation, accessed August 29, 2025, https://mpnresearchfoundation.org/news/cardiovascular-risk-and-mpns/
58. Thrombosis/Blood Clots | Richard T. Silver MD Myeloproliferative Neoplasms Center, accessed August 29, 2025, https://silvermpncenter.weill.cornell.edu/patients/conditions-and-complications/thrombosisblood-clots
59. Cardiovascular Risk Factors Increase Thrombosis, Mortality in Patients With Myelofibrosis, Other MPNs - Pharmacy Times, accessed August 29, 2025, https://www.pharmacytimes.com/view/cardiovascular-risk-factors-increase-thrombosis-mortality-in-patients-with-myelofibrosis-other-mpns
60. Cardiovascular Risk Factors Impact Outcomes in MPNs, accessed August 29, 2025, https://www.ajmc.com/view/cardiovascular-risk-factors-impact-outcomes-in-mpns
61. Cardiovascular risk factors in myeloproliferative neoplasms: associations with survival and thrombotic outcomes | Blood Vessels, Thrombosis & Hemostasis | American Society of Hematology, accessed August 29, 2025, https://ashpublications.org/bloodvth/article/2/3/100051/535083/Cardiovascular-risk-factors-in-myeloproliferative
62. Gut-Heart Axis: The Role of Gut Microbiota and Metabolites in Heart Failure | Circulation Research - American Heart Association Journals, accessed August 29, 2025, https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.125.325516
63. Gut Microbiota Metabolites and Risk of Major Adverse Cardiovascular Disease Events and Death: A Systematic Review and Meta-Analysis of Prospective Studies, accessed August 29, 2025, https://www.ahajournals.org/doi/10.1161/jaha.116.004947
64. How poor gut health increases heart disease risk: Early warning signs you should know, accessed August 29, 2025, https://timesofindia.indiatimes.com/life-style/health-fitness/health-news/how-poor-gut-health-increases-heart-disease-risk-early-warning-signs-you-should-know/articleshow/123559180.cms
65. The Impact of Gut Microbiota Modulation on Cardiovascular Risk: A Systematic Review., accessed August 29, 2025, https://healthcare-bulletin.co.uk/article/the-impact-of-gut-microbiota-modulation-on-cardiovascular-risk-a-systematic-review--3149/
66. Intestinal Insights: The Gut Microbiome's Role in Atherosclerotic Disease: A Narrative Review - MDPI, accessed August 29, 2025, https://www.mdpi.com/2076-2607/12/11/2341
67. (PDF) Trimethylamine N-Oxide Generated by the Gut Microbiota Is Associated with Vascular Inflammation: New Insights into Atherosclerosis - ResearchGate, accessed August 29, 2025, https://www.researchgate.net/publication/339335321_Trimethylamine_N-Oxide_G

enerated_by_the_Gut_Microbiota_Is_Associated_with_Vascular_Inflammation_New_Insights_into_Atherosclerosis
68. The gut microbial metabolite trimethylamine N-oxide and ... - Frontiers, accessed August 29, 2025, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1085041/full
69. Gut microbiota in atherosclerosis: focus on trimethylamine N-oxide - PMC - PubMed Central, accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7318354/
70. The Role of the Gut Microbiome and Trimethylamine Oxide in Atherosclerosis and Age-Related Disease - MDPI, accessed August 29, 2025, https://www.mdpi.com/1422-0067/24/3/2399
71. The roles of trimethylamine-N-oxide in atherosclerosis and its potential therapeutic aspect: A literature review - PubMed Central, accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10655873/
72. Gut Microbiota-Derived TMAO: A Causal Factor Promoting Atherosclerotic Cardiovascular Disease? - PubMed, accessed August 29, 2025, https://pubmed.ncbi.nlm.nih.gov/36768264/
73. Gut Metabolite Trimethylamine-N-Oxide in Atherosclerosis: From Mechanism to Therapy, accessed August 29, 2025, https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2021.723886/full
74. Gut Microbiota-Derived TMAO: A Causal Factor Promoting Atherosclerotic Cardiovascular Disease? - MDPI, accessed August 29, 2025, https://www.mdpi.com/1422-0067/24/3/1940
75. erc.europa.eu, accessed August 29, 2025, https://erc.europa.eu/news-events/news/gut-microbiota-metabolite-linked-atherosclerosis-could-revolutionise-diagnosis-and#:~:text=A%20new%20study%20led%20by.behind%20most%20heart%20attacks%20and
76. Gut microbiota-derived imidazole propionate: an emerging target for the prevention and treatment of cardiometabolic diseases - Frontiers, accessed August 29, 2025, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2025.1409119/full
77. A molecule produced by gut microbes may help spur heart disease - Science News, accessed August 29, 2025, https://www.sciencenews.org/article/heart-disease-gut-microbes-plaques
78. A gut microbiota metabolite linked to atherosclerosis could revolutionise diagnosis and treatment, accessed August 29, 2025, https://erc.europa.eu/news-events/news/gut-microbiota-metabolite-linked-atherosclerosis-could-revolutionise-diagnosis-and
79. An Unexpected Culprit in Heart Disease? Meet Your Gut Microbes - Promega Connections, accessed August 29, 2025, https://www.promegaconnections.com/an-unexpected-culprit-in-heart-disease-meet-your-gut-microbes/

80. Gut Microbiota and Cardiovascular Disease | Circulation Research, accessed August 29, 2025, https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.120.316242
81. The Gut Microbiota (Microbiome) in Cardiovascular Disease and Its Therapeutic Regulation, accessed August 29, 2025, https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2022.903570/full
82. Full article: Gut microbiome and its meta-omics perspectives: profound implications for cardiovascular diseases, accessed August 29, 2025, https://www.tandfonline.com/doi/full/10.1080/19490976.2021.1936379
83. Can Your Gut Health Affect Your Heart? | Johns Hopkins Medicine, accessed August 29, 2025, https://www.hopkinsmedicine.org/health/wellness-and-prevention/can-your-gut-health-affect-your-heart
84. Linking Air Pollution and Heart Disease | US EPA, accessed August 29, 2025, https://www.epa.gov/sciencematters/linking-air-pollution-and-heart-disease
85. Non-Traditional Cardiovascular Risk Factors: Tailored Assessment and Clinical Implications, accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12111945/
86. Cardiovascular diseases (CVDs) - World Health Organization (WHO), accessed August 29, 2025, https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
87. Environmental Pollutants as Emerging Concerns for Cardiac Diseases: A Review on Their Impacts on Cardiac Health - MDPI, accessed August 29, 2025, https://www.mdpi.com/2227-9059/13/1/241
88. Environmental Pollution and Cardiovascular Disease: Part 1 of 2: Air Pollution | JACC, accessed August 29, 2025, https://www.jacc.org/doi/10.1016/j.jacadv.2023.100805
89. Ambient air pollution and cardiovascular diseases: An umbrella ..., accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9310863/
90. Air Pollution and Cardiovascular Disease Basics | US EPA, accessed August 29, 2025, https://www.epa.gov/air-research/air-pollution-and-cardiovascular-disease-basics
91. Air Pollution, Heart Disease and Stroke - American Heart Association, accessed August 29, 2025, https://www.heart.org/en/health-topics/consumer-healthcare/what-is-cardiovascular-disease/air-pollution-and-heart-disease-stroke
92. Air particulate matter and cardiovascular disease: the epidemiological, biomedical and clinical evidence - PMC, accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4740122/
93. Particle Pollution and Cardiovascular Effects | US EPA, accessed August 29, 2025, https://www.epa.gov/pmcourse/particle-pollution-and-cardiovascular-effects
94. Air particulate matter and cardiovascular disease: the epidemiological, biomedical

and clinical evidence - Du, accessed August 29, 2025, https://jtd.amegroups.org/article/view/5883/6190
95. Particulate Matter Air Pollution: Effects on the Cardiovascular ..., accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6250783/
96. Cadmium and cardiovascular disease: An overview of pathophysiology, epidemiology, therapy, and predictive value | Revista Portuguesa de Cardiologia (English edition) - Elsevier, accessed August 29, 2025, https://www.elsevier.es/es-revista-revista-portuguesa-cardiologia-334-articulo-cadmium-cardiovascular-disease-an-overview-S0870255121002250
97. Cadmium and cardiovascular disease: An overview of ..., accessed August 29, 2025, https://www.revportcardiol.org/en-cadmium-cardiovascular-disease-an-overview-articulo-S2174204921002221
98. Contaminant Metals as Cardiovascular Risk Factors: A Scientific Statement From the American Heart Association, accessed August 29, 2025, https://www.ahajournals.org/doi/10.1161/JAHA.123.029852
99. Cadmium Exposure: Mechanisms and Pathways of Toxicity and Implications for Human Health - MDPI, accessed August 29, 2025, https://www.mdpi.com/2305-6304/12/6/388
100. Cadmium Exposure and Cardiovascular Diseases | Chemical Research in Toxicology, accessed August 29, 2025, https://pubs.acs.org/doi/10.1021/acs.chemrestox.3c00184
101. Mechanisms of lead-induced hypertension and cardiovascular ..., accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2519216/
102. Mechanisms of lead-induced hypertension and cardiovascular disease, accessed August 29, 2025, https://journals.physiology.org/doi/abs/10.1152/ajpheart.00158.2008
103. Mechanisms of lead-induced hypertension and cardiovascular disease - PubMed, accessed August 29, 2025, https://pubmed.ncbi.nlm.nih.gov/18567711/
104. Lead-Induced Hypertension - American Heart Association Journals, accessed August 29, 2025, https://www.ahajournals.org/doi/10.1161/01.HYP.30.6.1487
105. Cardiovascular System Inflammaging Mechanisms and Emerging Targets, accessed August 29, 2025, https://www.scholarsliterature.com/journals/international-journal-of-integrative-cardiology/fulltext/cardiovascular-system-inflammaging-mechanisms-and-emerging-targets
106. Non-Traditional Risk Factors as Contributors to Cardiovascular Disease - ResearchGate, accessed August 29, 2025, https://www.researchgate.net/publication/370757181_Non-Traditional_Risk_Factors_as_Contributors_to_Cardiovascular_Disease/download
107. Non-Conventional Risk Factors: “Fact” or “Fake” in Cardiovascular Disease Prevention?, accessed August 29, 2025, https://www.mdpi.com/2227-9059/11/9/2353
108. Cardiovascular disease – the role of inflammation and oxidative stress - Cytoplan Blog, accessed August 29, 2025,

https://blog.cytoplan.co.uk/cardiovascular-disease-the-role-of-inflammation-and-oxidative-stress/
109. Oxidative stress and cardiovascular disease: New insights | Request PDF - ResearchGate, accessed August 29, 2025, https://www.researchgate.net/publication/323780883_Oxidative_stress_and_cardiovascular_disease_New_insights
110. Cerebral signatures of cardiovascular disease: distinct brain lesion patterns in atrial fibrillation and atherosclerosis | European Heart Journal | Oxford Academic, accessed August 29, 2025, https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaf551/8243844
111. Oxidative Stress and Cardiovascular - Creative Diagnostics, accessed August 29, 2025, https://www.creative-diagnostics.com/oxidative-stress-and-cardiovascular.htm
112. Oxidative Stress in Cardiovascular Diseases: Still a Therapeutic Target? - MDPI, accessed August 29, 2025, https://www.mdpi.com/2072-6643/11/9/2090
113. Oxidative Stress in Cardiovascular Diseases - PMC, accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7554855/